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ABSTRACT 
HIV and AIDS has severely inflicted suffering on the global population and reported to 
be the worst killer disease in sub-Saharan Africa. Preventive measures such as condom 
use among young people is still low and less effective in preventing the spread of the 
disease, it was recommended by the United Nations General Assembly Special Session 
on HIV and AIDS (2001) to accelerate the development of HIV vaccine aimed at curbing 
the disease. This study sought to explore young women’s experiences and perceptions 
about HIV prevention vaccine clinical trials so as to inform the design and 
implementation of vaccine trials in Africa. The study employed purposive sampling to 
interview 27 participants using semi-structured interview schedule. A tape recorder was 
used to capture data and coding procedures were used to analyze data. 
Findings drawn from participants’ responses and compared with literature from previous 












to join HIV prevention vaccine clinical trials because they hope to be protected from HIV 
infection. Most importantly participants hope to get access to medical care and treatment, 
meanwhile some participants perceived HIV vaccines harmful to humans hence they 
usually decline to participate. The study also identified study participation challenges 
related to socio-cultural and historical aspects. 
Although vaccines have had some success stories in the prevention and control of 
infectious diseases such as the eradication of polio, smallpox and measles, prevailing 
challenges need to be addressed if vaccine development is to be feasible. Providing more 
information, reinforcement of community awareness and mobilization around issues of 
HIV vaccine clinical trials at all levels of vaccine design and implementation is required 
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This chapter introduces the topic of the study being the exploration of the perception and 
experiences of young women about participating in HIV prevention vaccine clinical in 
Nyanga Township, Cape Town, South Africa. The chapter presents the background of the 
problem under study and the rationale for undertaking the study. The main research 
questions and objectives have been outlined, key concepts have been clarified and ethical 
considerations have also been discussed.  
1.1 Background and Context  
This study sought to explore the perceptions and experiences that young women have 
about participating in HIV and AIDS prevention vaccine clinical trials in Nyanga 
Township Cape Town in the Western Cape, South Africa.  
It is estimated that globally 34 million people were living with HIV by the end of 2010 
(UNAIDS, 2011) and sub-Saharan Africa remains the region most heavily affected by 
HIV and where it is still the major cause of deaths (UNAIDS, 2011). Accordingly, in 
2009, over 40% of new adult infections with HIV occurred in young people between the 
ages of 15 and 24, amounting to 890,000 new infections in that age group during that 
year (UNICEF, 2010). Basically, HIV and AIDS scourge has had adverse implications on 












The Southern Africa sub-region, particularly, experiences the most severe HIV epidemics 
in the world, with one third (34 per cent) of all people living with HIV globally residing 
in the 10 countries of Southern Africa (UNAIDS, 2010).  
According to UNAIDS (2011) the AIDS epidemic has had a unique impact on women, 
which has been exacerbated by their role within society and their biological vulnerability 
to HIV infection. Research has also found that women are at a greater risk of 
heterosexual transmission of HIV and biologically women are twice more likely to 
become infected with HIV through unprotected heterosexual intercourse than men. In 
many countries women are less likely to be able to negotiate condom use and are more 
likely to be subjected to non-consensual sex (UNAIDS, 2011). The Bill of Human Rights 
contained in the South African Constitution (1996) gives every South African citizen a 
right to access to health care and health related services such as water. But the reality on 
the ground is that people are still faced with constraints such as poor access to decent 
basic health care services.  
The American Association for the Advancement of Science and Physicians for Human 
Rights and Health (1988) reports on the apartheid regime in South Africa indicate that 
laws and policies at the time affected all aspects of the people’s lives, the health sector 
not being an exception. The South African health care system not only limited access to 
health care for Blacks and often ignored quality-of-care guidelines, which caused major 
disparities in health care. During apartheid, most of the national health expenditure was 












the privately insured. It was noticed that privately insured patients pay a highly 
subsidized fee for medical care and receive tax benefits for their contributions to the 
private health sector (Zeida and Nuha, 2008). 
Based on such reports, in the generally resource-poor settings where HIV prevention 
trials are being conducted, it is critically important to recognize the historical backdrop of 
apartheid and racism, and on-going challenges of poverty and exploitation. 
Across the sub-Saharan Africa, some countries have achieved notable reductions in HIV 
prevalence among young people (15–24 years), notably, HIV prevalence among young 
women and men fell by 42% from 2001 to 2012. However, despite these advances, still 
too many people are acquiring HIV infection, too many people are getting sick and too 
many people are dying from HIV and prevalence among young women remains more 
than twice as high as among young men throughout sub-Saharan Africa (UNAIDS, 
2011). 
In response to the global outcry the United Nations General Assembly Special Session on 
HIV and AIDS (2001) recommended that increase in investment HIV vaccine 
development be accelerated (United Nations General Assembly Special Session on HIV 
and AIDS, 2001). The UNAIDS (2010) published evidence from clinical trials confirmed 
the powerful impact antiretroviral drugs have on the epidemic as part of an effective 
package of options for HIV prevention. The report shows that for first time, the prospect 
of a microbicide that contains antiretroviral medicine is providing additional hope to 












epidemic in this region. This confirms the findings in the UNAIDS (2011) report that 
suggests that there is a remarkable decline in the number of people being infected. It is 
further stated that a total of 2.7 million people acquired HIV infection in 2010, down 
from 3.1 million in 2001, contributing to the total number of 34 million people living 
with HIV in 2010 (UNAIDS, 2011). 
According to Ethics in Health Research report (UNAIDS, 2012), the purpose of an HIV 
preventive vaccine is to induce an immunological response to counteract the HIV virus if 
it enters the human body, or to prevent it from entering at all. Since HIV prevention 
vaccine trials require that several injections be given over months or years, this 
sometimes result in pain, occasional skin disorders and possibly other adverse events, 
such as fever may be sustained due to clinical procedures related during the course of the 
clinical trials. 
1.2 Statement of the Research Problem 
Although HIV prevalence is stabilizing and declining in some countries, Southern Africa 
still experiences higher incidences of HIV infections estimated at 31% of new infections 
and 34% of AIDS deaths (UNAIDS, 2010). Reports indicate that not only is HIV 
epidemic a global crisis, but also has also had adverse effects on the development and 
social progress of the global economy. Not only does HIV present a tragedy at human 
level but it also heavily affects the economic development of countries, many of which 












As the HIV and AIDS epidemic rages globally, it is becoming increasingly clear that 
treatment such as antiretroviral therapy cannot control the worldwide spread of HIV, nor 
will HIV transmission be stopped through behavioral interventions alone. First, safe and 
effective vaccines to prevent HIV infection and AIDS are necessary to control the spread 
of the disease (de Zoysa, Elias & Bentley, 1998).  Second, although some notable 
achievements have been made in HIV management, including substantial improvements 
in access to condoms, expansion of tuberculosis control efforts and scale-up of free 
antiretroviral therapy, an HIV and AIDS vaccine would have a number of key advantages 
over the existing HIV prevention options. These arguments are based on the fact that 
protection offered by a vaccine during sex would not depend on the consent of both 
partners, unlike the use of condoms or adherence to abstinence which would require 
behaviour change (Abdool Karim, 2005; UNAIDS, 2010).  
1.3 Rationale of the Study 
Various studies have shown tha  there is little information about factors that motivate 
young people who had gone to participate in HIV vaccine clinical trials to do.  For 
example a report on a study conducted by Starac et al., (2006) in 72 high public high 
schools in Soweto (2005) on adolescents and HIV vaccine trials shows that participants 
have little knowledge about HIV clinical trials.  Findings from the study show that 
participants had inadequate information communicated to them at enrolment. These 
studies hence highlight the importance of clear identification of motivations and 
incentives that may facilitate participation in vaccine clinical. Various studies have 












participation in clinical trials. These factors are, in general, linked to altruistic feelings, 
the perception of personal benefits and satisfactory interaction with the study staff 
(Celentano, 1995; Jenkins, 1995; MacQueen, 1999; Pe´risse´, 2000; &Strauss, 2001 cited 
in Starac, 2006).  
This study focused on young women aged 18-24 years perceptions and experiences about 
participating in HIV prevention vaccine clinical trials. The fact that young women accept 
to participate in clinical trials should not compromise their rights in the long-run. For that 
matter, identification and consideration of potential barriers is paramount when designing 
procedures and guidelines to be followed in the recruitment into vaccine trial studies.  
International AIDS Vaccine Initiative (IAVI) and Int rnational Centre for Research on 
Women (ICRW) (2008) highlight some of the barriers to vaccine trial participation. 
These include a collection of psychological and social factors that may discourage 
someone from participating in a vaccine trial. Although this study is focusing on young 
women, it is recognized that men also get affected either directly as participants or 
indirectly as relatives to the clinical trial participants (IAVI and ICRW, 2008). 
The overall aim a d objective of this study was to explore young women’s experiences 
and perceptions about HIV prevention clinical trials. Information gathered from this 
study may be used to inform the design and implementation of HIV vaccines trial 













1.4 Specific Objectives of the Study  
The main research objectives are: 
 To find out the reasons why young people participate in HIV prevention vaccine 
clinical trials 
 To explore young women’s perceptions about of HIV prevention vaccine clinical 
trials 
 To explore young women’s experiences regarding their participation in HIV 
prevention vaccine clinical trials 
 To explore young women’s attitudes about in HIV prevention vaccine clinical 
trials 
 To identify factors that influence women’s decision to participate or not to 
participate in HIV prevention vaccine clinical trials 
 To identify the challenges and barriers that participants encounter while 
participating in HIV prevention vaccine clinical trials  
 To identify whether study participants are knowledgeable about the risks, benefits 
and rights related to participating in HIV prevention vaccine clinical trials  
 To assess whether study participants are aware of the policies that relates to HIV 













1.5 Main Research Questions  
The main research questions are: 
 What are the reasons and motivations that inspire young women to participate in 
HIV prevention vaccine clinical trials? 
 What are the young women’s perceptions and experiences of HIV prevention 
vaccine clinical trials? 
 What are the young women’s attitudes towards participating in HIV prevention 
vaccine clinical trials? 
 What are the subjective norms that influence women’s decision to participate or 
not to participate in HIV prevention vaccine clinical trials? 
 What are the young women’s challenges and barriers related to participating in 
HIV prevention vaccine clinical trials? 
 Are young women aware of the risks, benefits and rights related to participating in 
HIV prevention vaccine clinical trials? 















1.6 Significance of the Study 
Sub-Saharan Africa remains the region most heavily affected by HIV, accounting to 70% 
of new HIV infections in 2010 (UNAIDS, 2011). In sub-Saharan Africa, the epidemic 
continues to be most severe in southern Africa, with South Africa having more people 
living with HIV (estimated at 5.6 million) than any other country in the world. And of the 
people living with AIDS, 518 000 are children under 15 years while 2.95 million were 
females over the age of 15 years and worse still, almost half of the deaths from AIDS-
related illnesses in 2010 occurred in southern Africa (UNAIDS, 2011). 
Since as many as 34 million people are infected with HIV w rldwide (UNAIDS, 2011) 
the vaccine is still the best hope for eradicating AIDS (International AIDS Vaccine 
Conference, 2012). A report by International AIDS Vaccine Initiative (IAVI) (2006) 
explains that even a partially effective HIV vaccine could save millions of lives. Experts 
have calculated that a vaccine that is 50 percent effective, given to just 30 percent of the 
population could reduce the number of HIV infections in the developing world by more 
than half over 15 years (IAVI, 2006).  
Accordingly, studies have found that an HIV and AIDS vaccine would have a number of 
key advantages over today’s HIV prevention options. International AIDS Vaccine 
Initiative (IAVI) reports show that once found, an HIV vaccine would be invaluable for 
couples wishing to conceive a child while minimizing the risk of HIV transmission, and 
children could be given an HIV and AIDS vaccine before ever being exposed to HIV to 












large numbers of people would probably require relatively little equipment and expertise, 
and would be much simpler and cheaper than providing antiretroviral treatment for those 
already infected (IAVI, 2006).  
Based on the above statements, therefore, the search for an effective AIDS vaccine needs 
to be one of the highest priorities for scientific research.  
1.7 The Research Topic 
The research topic is “An exploration of young women’s perceptions and experiences of 
participating in HIV prevention vaccine clinical trials in Nyanga Township in the 
Western Cape, South Africa”. The research topic clarifies what the researcher intends to 
study and it explains whether the research explores new ideas or describes existing 
phenomena and the practical significance of the study (Babbie & Mouton, 2001). The 
proposed study is exploratory and of a contextual design. The researcher expects the 
study to contribute findings that will contribute to useful information about young women 
decisions to participate in HIV vaccine clinical trials. 
1.8 Concept Clarification/Definition of Terms 
The following terms will be used repeatedly in this study. For the purposes of further 
understanding of the topic in this study key concepts have been clarified. 
AIDS. According to the dominant and current definition of AIDS offered by the by the 
Centers for Disease Control (CDC) in the United States, AIDS stands for acquired 












opportunistic infections and cancers and for which, to date, there is no cure (Harold, 
1995) 
Clinical Research: This is a health related research conducted on human beings or on 
specimens collected from specific patients, but not on human tissues, where the identity 
of the people from whom the cells or tissues are derived is unknown (Harold, 1995)  
Clinical Trials: These are organized experiments in which outcomes in participants who 
are assigned active treatment are compared with those receiving an alternative active 
treatment, a placebo (inactive treatment) or no treatment (Harold, 1995). 
The Human Immunodeficiency Virus (HIV): This is a retrovirus that infects cells of the 
immune system, destroying or impairing their function. As the infection progresses, the 
immune system becomes weaker, and the person becomes more susceptible to infections. 
The most advanced stage of HIV infection is the acquired immunodeficiency syndrome 
(AIDS) (WHO, 2006). 
 HIV Vaccines: These stimulate the body’s immune system to provide protection against 
infection or disease. Vaccines against HIV are being developed, and they are in various 
stages of clinical trial but at present none have proven effective (WHO, 2009).  
Township: According to the South African meaning of township (often underdeveloped), 
this refers to urban residential area in which the non-white inhabitants used to live during 
times of the apartheid. However, the term township also has a precise legal meaning, and 












Young Women (youth): The National Youth Policy (NYP) 2009 – 2014, defines the youth 
as the youth people falling within the age group of 14 to 35 years.  While “the youth” or 
“young people” are defined as the 14–35 age cohort in South Africa, taking into account 
both historical as well as present-day conditions, this study will focus on the 15–24 age 
group with its very specific characteristics and needs in terms of the school-to-work 
transition. 
1.9 Structure of the Report 
The research report has been structured as follows:  
Chapter One: Introduction. This chapter introduces the research problem. A brief 
background of the research problem has been given, followed by the statement of the 
problem, rational and aim for the study, ethical considerations, research topic, main 
research objectives, research questions, definition of key terms, list of abbreviations and 
layout of the research report.  
Chapter Two: Literature Review. This chapter presents a review of the literature relating 
to the research topic, the theoretical frameworks to be used for conceptualization and 
analysis of the data. This chapter is structured around the research themes namely HIV 
prevention clinical vaccine trials from a global perspective, the South African context and 
specially Cape Town in Nyanga Township.   
Chapter Three: Methodology. This chapter presents the research methodology by 
discussing the research design, sampling considerations, data collection methods, data 












Chapter Four: Findings. This chapter presents the research findings. Firstly a profile of 
the participants is presented, followed by framework of analysis, discussion of the 
findings placed under headings, which relate to the main themes and categories in the 
framework of analysis.   
Chapter Five: Conclusions and Recommendations. The chapter uses the research 
objectives to discuss the conclusions that emanated from the findings. The chapter also 

























In order to determine what has already been done that relates to the research topic, it is 
significant for the researcher to review the existing literature that is related to the topic 
being researched. This knowledge helps the researcher from intentionally duplicating 
another person’s research as well as providing the researcher with an understanding and 
insight needed to ascertain what has been and what needs to be done and identify 
knowledge gaps. According De Vos (2011) literature review sheds light into the nature 
and meaning of the problem that has been identified. In order to understand the concept 
of HIV vaccine clinical trials the researcher has drawn on various theoretical frameworks 
as will be explained later in the subsequent paragraphs.  
2.1 Global HIV and AIDS Responses 
At the end of 2010, it was estimated that out of the 34 million adults worldwide living 
with HIV and AIDS, half are women (UNAIDS, 2011). The AIDS epidemic has had a 
unique impact on women, which has been exacerbated by their role within society and 
their biological vulnerability to HIV infection (UNAIDS, 2013). Women are at a greater 
risk of heterosexual transmission of HIV and biologically women are twice more likely to 
become infected with HIV through unprotected heterosexual intercourse than men 
(Dworkin, 2005 and Zierler, Krieger, 1997). In some countries, women are less likely to 
be able to negotiate condom use and are more likely to be subjected to non-consensual 












The UNAIDS (2009) report adds that millions of women have been indirectly affected by 
the HIV and AIDS epidemic. Women’s childbearing role means that they have to contend 
with issues such as mother-to-child transmission of HIV. The responsibility of caring for 
people living with AIDS and taking care of orphans is an emerging challenge for women. 
Based on the above arguments, a number of things need to be done that in order to reduce 
the burden of the epidemic among women. These include promoting and protecting 
women's human rights, increasing education and awareness among women and 
encouraging the development of new preventative technologies such as post-exposure 
prophylaxis and microbicides (UNAIDS, 2009). 
2.2 HIV and AIDS Strategies and Interventions  
Because of the formidable and persistently unique threat and challenge the HIV and 
AIDS poses globally, the UNAIDS (2011) report highlights unprecedented global 
response to further fight against the scourge. These innovative interventions include the 
Political Declaration on HIV and AIDS, adopted in June 2011 by the United Nations 
General Assembly, which sets ambitious targets aimed at achieving universal access and 
the health-related Millennium Development Goals by 2015; The World Health 
Organization (WHO) Global Health Sector Strategy on HIV and AIDS, 2011-2015, the 
UNAIDS 2011-2015 Strategy: Getting to Zero, and the UNICEF’s strategic and 
programmatic focus on equity aimed at helping to guide national and global efforts to 
respond to the epidemic and move from an emergency response to a long-term, 
sustainable model of delivering HIV services. These strategies emphasize the need to 












bring them closer to people in need and to integrate with other health and community 
services to achieve the greatest impact (UNAIDS, 2011).  
2.3 Global HIV and AIDS Vaccine Clinical trials as New Prevention Tools  
As the AIDS epidemic continues to expand, especially in sub-Saharan Africa initiatives 
to reduce HIV incidence are also being accelerated, reference give to the endorsement of 
the 2011 UN Political Declaration on HIV/AIDS, which set forth a series of ambitious 
targets and elimination commitments for 2015 (UNAIDS, 2013). Although prevention 
campaigns that promote Abstinence, Being faithful and using Condoms (ABC), male 
circumcision and the testing of microbicides are being emphasized as some of the current 
measures towards the fighting of the HIV and AIDS epidemic, studies have shown that 
the best hope to end the AIDS epidemic is the development and distribution of effective 
vaccines (IAVI, 2006).  
In 2000, the Security Council of the United Nations began to address the possibility that 
by devastating a country's entire population of young adults, AIDS now threatens the 
world's security. Besides the immediate crisis that HIV presents, it also undermines 
global development, nullifying or even reversing decades of progress that most likely 
lead to deepening poverty, reducing life expectancy, contributing to economic and 
political instability, exacerbating food shortages and increasing the divide between the 
rich and the poor (Kahn, 2005).  
Against this background, response to curtail HIV prevalence has become a critical and 












renowned leaders, Bill Clinton, pointed out that despite recent developments in averting 
the HIV scourge, control of AIDS still awaits a vaccine. In 1997, President Bill Clinton 
challenged scientists to provide an effective vaccine and as a result a national HIV 
Vaccine Trials Network was established to develop and test possible compounds (Kent et 
al., 2001). This development, however, was associated with challenges to researchers 
such as establishing viral heterogeneity, uncertainty about how to achieve optimal 
immunogenicity, the lack of a practical animal model, and the ethical dilemmas involved 
in conducting primary prevention trials in the United States and abroad (Kent et al., 
2001). AIDS Vaccine Advocacy Coalition also warned that though the HIV vaccine 
remains the world’s best chance to reverse this relentless epidemic, the search a vaccine 
must not come at the expense of our immediate response (Kahn, 2005). 
Testing vaccines requires that efforts be directed towards delivering the best possible 
risk-reduction counselling and prevention tools, ensuring confidential voluntary 
counselling and testing, providing referral to comprehensive treatment. Additionally, in 
order to marshal and sustain public involvement in global AIDS efforts, communities 
need information that not only educates but also suggests how people can play an active 
role (Kahn, 2005).  
In response to the escalation of the HIV epidemic, the UNAIDS (2008) reports that in 
2000, global leaders embraced a series of Millennium Development Goals (MDG) that 
reflected new found resolve to make the world safer, healthier, and more equitable. 












begun to reverse the global HIV epidemic. By making the HIV response one of the 
overriding international priorities for the 21st century, world leaders acknowledged the 
centrality of the HIV response to the future health and well-being of our increasingly 
interconnected planet (UNAIDS, 2008). While national programmes work to bring 
available HIV prevention strategies to scale and to improve their strategic application, the 
search continues for additional tools to strengthen prevention efforts. In particular, new 
prevention technologies are urgently needed, more especially for women who currently 
lack access to female-initiated prevention methods (UNAIDS, 2008).    
The HIV and AIDS vaccine agenda is increasingly part of some larger agenda that 
agenda includes alleviating poverty and promoting development and economic growth; 
and promotion of social equity (Kahn, 2005). However, much as vaccine discovery seems 
to be a desired direction against HIV prevention, enough efforts have not been made to 
make it work. This is evidenced in AVAC’s remarks that AIDS vaccine development has 
not received enough attention or funding since the discovery of HIV and rarely gets 
government action or support (Kahn, 2005). Scientific uncertainties over what is likely to 
work, plus doubts about the profitability of an AIDS vaccine, have discouraged the 
involvement of pharmaceutical companies, which traditionally led the way in making 
new vaccines (Kahn, 2005). Vaccine developers cannot predict what strategy will work 
or even whether they are going in the right direction or heading down to a dead end. The 
only way to find out is to test vaccines in populations of HIV negative people exposed to 
HIV through different routes, for example, gay men exposed through anal sex and 












is ethically complex because HIV prevention clinical trials involve international 
collaborations, potentially vulnerable communities and participants, and high levels of 
discrimination and stigma surrounding HIV (Slack et al., 2000).  
Since HIV vaccine testing also raises significant human rights issues, it is critical the 
International Ethical Guidelines developed by UNAIDS be adhered to. The publication of 
the Nuremberg Code 6 in 1947 and the subsequent to the Declaration of Helsinki in 1964 
recognize that research should be regulated by some type of ethical-legal framework. 
However, the nature and extent of regulation varies from country to country (Strode, 
Slack & Mushariwa, 2005). In South Africa, National Health Research Committee 
(NHRC), established in terms of Section 69 of the National Health Act is a policy-
formulating body that advises the Minister of Health on the nature and focus of health 
research within South Africa and co-ordinate such efforts (Department of Health, 2003). 
The HIV and AIDS Vaccines Ethics Group research the ethical aspects of HIV vaccine 
trials and develop guidelines to assist in the practice of ethically sound HIV vaccine trials 
(Slack et al., 2000).  
2.4. Reasons why Young People Participate in HIV Vaccine Clinical Trials 
Vaccine trial participation is a complex process that involves barriers and motivators. To 
gain a comprehensive understanding of potential and actual trial participants, we need to 
build on Mills et al, (2005) work on barriers and examine the related literature on 
motivators. For example, altruism and health insurance (Sahay, Mehendale &Sane et al., 












infection, making a contribution towards the fight against HIV and AIDS, the hope to 
receive free medical attention and financial incentives (McGrath, Mafigiri, & Kamya et 
al., 2001) and to get protection from HIV infection (Mills, Cooper & Guyatt, et al., 2004) 
are often identified as a motivators. These findings further show that the design and 
implementation of vaccine trials benefit from a better understanding of these motivators, 
and efforts to engage these motivators ethically.  
The Medical Research Council outlines ethical guidelines for potential benefits that 
participants in HIV preventive vaccine trials should receive as a result of their 
participation. These include facilitating regular and supportive contact with health-care 
workers and counsellors throughout the course of the trial; receiving comprehensive 
information regarding HIV transmission and how it can be prevented, and access to 
appropriate HIV prevention methods, accessibility to treatment and care for HIV and 
AIDS if they become HIV infected while enrolled in clinical trial studies and getting 
compensation for travel, time and inconvenience relating to trial participation (Slack, C. 
and Kruger, M. (2005).   
2.5 Perceptions of HIV and AIDS Vaccine Clinical Trials 
In South Africa, differences exist in status, knowledge and power between investigators 
and research participants, especially where participating individuals and communities are 
vulnerable because of socio-economic and other factors (UNAIDS, 2000). Meaningful 
involvement of communities in research can serve to offset the vulnerability of 












and responsibility to take decisions regarding the nature of their participation in HIV 
vaccine research (UNAIDS, 2000). There should be community participation in all 
relevant aspects of HIV vaccine research and investigators must clearly justify and 
explain those aspects of research that are essential to a scientifically valid and ethically 
sound research design (UNAIDS, 2000). For that matter, the social context of a proposed 
research population that creates conditions for possible exploitation or increased 
vulnerability among potential research participants should be assessed and where this is 
applicable, steps must be taken to overcome these conditions with the aim of promoting 
and protecting the dignity, safety and welfare of participants. In South Africa, like other 
developing nations, many individuals at high risk of HIV infection may be 
simultaneously vulnerable to exploitation because of socio-historical factors, such as 
oppression and economic impoverishment (UNAIDS, 2000). 
Research in developing countries about clinical research has found that due to the risk of 
inadvertent or deliberate exploitation, a cautionary approach should be followed when 
conducting research with human participants in developing countries. According to 
Glantz (2001) cited in Starac (2006) citizens of developing countries are often in 
vulnerable situations because of their lack of political power, lack of education, 
unfamiliarity with medical interventions, extreme poverty, or need for health care health 
care and nutrition. It is the dire need of these populations that make them both 
appropriate participants of research, especially those vulnerable to exploitation (Glantz, 












This combination of need and vulnerability has led to the development of specific 
guidelines for health research in developing countries. Despite codes of ethics and 
regulations, there is on-going evidence of unethical recruitment and research practice. 
(LaFraniere, Flaherty & Stephens et al (2000) cited in Starac (2006).This malpractice 
generally violates the autonomy of research participants and targets the vulnerable 
subgroups of a given population as is evidenced with the legacy of apartheid in South 
Africa which is marred with reports of unethical research conducted and may have 
impacted negatively on public perceptions of the voluntariness of research participants. 
Specific ethical guidelines for HIV vaccine trials were published by UNAIDS (2000), 
and were revised and adapted for South Africa (Slack and Kruger, 2005). Special 
attention needs to be paid to the protection of participants’ autonomy in particular as 
noted by Jenkins (1985) who emphasizes that simple justice requires that each socio-
economic group bears a proportionate share of research risk, but many researchers fall 
into the trap of recruiting participants from dependent and less privileged populations. 
Developing countries, and particular communities within developing countries, arguably 
fall within this category (Jenkins et al., 1985). 
Studies conducted on volunteerism in clinical trials in South Africa suggest that 
community preparedness campaigns conducted prior to recruitment for clinical trials such 
as HIV prevention vaccine trials need to emphasize the voluntariness of enrolment in the 
trial and the freedom to withdraw at any time. These studies further point out that 
informed consent procedure should also highlight the voluntary component of trial 












elsewhere that found that very few participants recalled or understood key elements of 
the trial design (Ramjee, Morar & Alary et al., 2000). 
Merck and the US National Institute of Allergy and Infectious Diseases, part of the 
National Institutes of Health (NIH), the pharmaceutical company Merck & Co. Inc., and 
the NIAID-funded HIV Vaccine Trials Network (HVTN) announced that immunizations 
in the HIV vaccine clinical trial known as the STEP study, also referred to as the HVTN 
502 or Merck V520-023 study was discontinued basing on the decision made by an 
independent Data and Safety Monitoring Board (DSMB). This was because of the 
findings that the vaccine did not prevent HIV infection nor reduce the amount of virus in 
those who became infected with HIV (Kristen, 2005).   
2.6 Barriers and Challenges to Participation in Vaccine Clinical Trials 
Historically studies have shown that immunizations have not always been universally 
accepted and this is based on resistance to mandatory smallpox vaccination began in the 
1850s in the UK and towards the end of the 19th Century in the USA in response to 
enforcement of existing laws or creation of new ones (Wolfe & Sharp, 2003). It is further 
argued that after decades of relative acceptance of new vaccines, a strong anti-
vaccination movement began in the 1970s owing to adverse events from the whole-cell 
pertussis vaccine and this anti-vaccination sentiment continued into the subsequent 
decades (Poland et al., 2001).  
Based on the mentioned anti-vaccine movements it has been suggested that the 












the health belief model which can be used to predict decisions such as willingness to 
participate (WTP) in a trial (Poland, et al. 2001. Studies on HIV and AIDS vaccine trials 
have examined several barriers that may hinder people considering participation in HIV 
clinical trials. It is important that barriers are clearly understood from the onset of clinical 
trials for purposes of planning. Mills et al., (2004) points out that if researchers 
understand what factors could hinder potential participants in clinical studies, then it is 
possible for them to attend to those hindrances to avoid shortcomings in HIV prevention 
vaccine research processes. Mills et al., (2004) mentions that researchers, for example, 
can attend to potential harms and misconceptions related to participation in HIV vaccine 
trials, help eliminate these barriers, and enroll sufficient numbers of participants willing 
to participate. Emphasis should be given to the identification of potential barriers when 
designing informed consent procedures (Mills et al., 2004). For example, potential 
participants must understand that there may be side effects from the vaccine being tested, 
some participants becoming HIV sero-positive secondary to the HIV vaccine and that the 
vaccine efficacy is unknown (Lindegger & Richter, 2000).  
For example, a study on Organization for Economic Co-operation and Development 
(OECD) countries and the non-OECD countries, it was found that barriers to 
participation in HIV vaccine trials included personal risks, social risks, personal costs, 
social costs, and misconceptions. Concerns regarding adverse effects and vaccine-
induced sero-positivity were cited as outstanding barriers in both types of countries in 
various populations. In the OECD countries, men who have sex with men (MSM) cited 












common fears and hence barriers to participate in HIV clinical trials (Mills et al., 2004). 
Other examples include experiences based on the first Phase 1 HIV vaccine trial in 
Africa, which indicated a number of perceived barriers to participation and 
misconceptions about trial participation, including fears of deliberate infection with HIV 
(Mugerwa, Kaleebu, & Mugyenyi et al., 2002).  
Another potential barrier cited is mistrust of information about HIV vaccine provided by 
the government and researchers. In their findings, Newman et al., (2006) suggest that 
lack of transparency and false information has fostered mistrust of the government, 
science and health care in South Africa, posing potential barriers to participation in HIV 
vaccine clinical trials. 
The importance of ethics, communication and attending to societal concerns in health 
science research and ethical guidelines should therefore be emphasized. Since HIV 
vaccines are important long-term preventive measures aimed at combating the epidemic 
that has overwhelmed the world, it is imperative therefore, that vaccine trials in search of 
suitable and effective vaccines be designed and conducted according to high ethical 
standards. Additionally, HIV vaccine development should ensure that the vaccines are 
appropriate for use among such populations and Good Clinical Laboratory Practice 
(GCLP) should be adhered to for guidance (Slack and Kruger, 2005). On the international 
level, international guidance documents on research ethics such as the Declaration of 
Helsinki and guidelines (1964) and the guidelines of the Council for International 












rights such as the right to bodily integrity or to have access to interventions which prove 
effective, and other rights (Slack and Kruger, 2005). 
2.7 Rights to Participation in HIV Prevention Vaccine Clinical Trials 
In clinical research, trial participants are entitled to legal rights that must be adhered to by 
researchers. Independent and informed consent for participation, based on complete, 
accurate, and appropriately conveyed and understood information as well as its 
consequences, should be obtained from each individual who is legally competent to give 
consent (Slack and Kruger, 2005).  
Throughout the trial efforts must be made to ensure that participants continue to 
understand the consequences of participation and that they participate freely as the trial 
progresses. Some of the rights include empowering participants to make decisions that 
are consistent with their values and preferences. And before starting research a process of 
consultation between community representatives, investigators, research ethics 
committees, regulatory bodies, and sponsor(s) should be undertaken to design for 
effective implementation processes (Slack and Kruger, 2005).  
2.8 Benefits of Participating in HIV Prevention Vaccine Clinical Trials 
The ethical considerations in biomedical HIV prevention trials emphasize the importance 
of research protocol providing anticipated benefits of the procedures and interventions of 
clinical trials to anticipating trial participants (Slack and Kruger, 2005). It is re-enforced 
that the trial protocol outlines the expected services and other supplementary 












be in terms of support, care and treatment to participants and the community involved in 
HIV prevention clinical trials (UNAIDS 2000). 
Benefits to trials participants include regular contact with health care workers and 
counsellors throughout the course of the trial; participants receive comprehensive 
information regarding HIV transmission and how it can be prevented; have access to HIV 
testing and prevention methods (UNAIDS, 2000). 
2.9 Policies and Legislative Framework on HIV and AIDS Clinical Trials  
Although there is no specific policy in regard to HIV and AIDS vaccine clinical trials, the 
government has put in place general policy guidelines such as the National Strategic Plan 
(NSP, 2012-2016), whose strategic objectives among other include addressing social and 
structural barriers that increase vulnerability to HIV, STI and TB infection. The main 
goal of research on HIV, STIs and TB in South Africa in the new NSP is to provide 
scientific evidence to guide policy and enhance the country’s response to these diseases 
(NSP, 2012-2016). The Health Research Policy in South Africa has been developed to 
promote practice and conduct of research that contributes towards the improvement of the 
human health and welfare of the South African population (NSP, 2012-2016). 
At a macro level, the 2009–2014 Medium Term Strategic Framework (MTSF) sets to 
identify strategic priorities and targets that serve as the basis for determining the 
government’s implementation plans, while the National Planning Commission is a broad 
government framework for addressing the major developmental challenges in South 












At the international level, the Millennium Development Goals s have specific targets that 
all countries are striving to achieve by 2015. By situating the response to HIV, STIs and 
TB within the broader development agenda and integrating the human rights and gender 
dimensions, countries are in a better position to accelerate progress across an array of 
MDGs (NSP, 2012-2016). 
The strength of the various policies and legislation has however not always translated 
into enhanced or improved delivery on the ground. This phenomenon is more as a result 
of a lack of capacity at Local Government level than a deficiency in the policy 
environment. The National Youth Policy (2009) thus emphasizes the need for holistic 
intervention for the youth in South Africa which must target challenges of poverty, health 
and education. However, despite amplified attention on national and global policy 
agenda, few countries have been able to systematically reduce socially determined 
inequities in health (WHO, 2008). Further findings in the National Health Act, Act No. 
63 of (2003) show that although South Africa has a functioning ethical-legal system that 
has recently been strengthened through the implementation of the National Health Act, 
the ethical-legal framework, it does not have many of the laws needed to protect and 
promote the rights of persons participating in research, including HIV prevention vaccine 
trials (Government Gazette, 2004).  The researcher, therefore, suggests that future effort 
must be directed at enhancing the ability of the South African ethical-legal system to 













2.10 Theoretical Framework  
HIV and AIDS prevalence poses a challenge to the South African health sector and 
communities. It is of paramount importance for the health sector to design interventions 
aimed at alleviating this scourge. These interventions should be derived from well-tested 
theories. To try and understand how health behaviours act as catalysts towards the way 
individuals preserve or enhance their health, the researcher will use commonly known 
and relevant theories to help us understand health behaviour. These Reasoned Action 
(TRA) and Planned Behaviour (TPB) (Ajzen, 1988; Fishbein & Ajzen, 1975). The 
researcher has chosen the TRA and TPB for this study since they are some of the most 
cited theories in HIV and AIDS research.  
These theories are more reliable in predicting HIV and AIDS health behaviour than other 
models (Fishbein, 1993). This particular study is about HIV prevention vaccine trials, the 
researcher finds it relevant to apply the TRA and TPB theories.  
2.10.1 Overview of Theory of Reasoned Action (TRA)  
The Theory of Reasoned Action was first introduced in 1967 by Fishbein in an effort to 
understand the relationship between attitude and behaviour (Fishbein & Ajzen, 1975). 
The Theory of Reasoned Action was based on the premise that humans are rational and 
that the behaviours being explored are under volitional control (Fishbein & Ajzen, 1975). 
The TRA attempts to explain the relationship between beliefs, attitudes, intentions and 












distinguished between attitude towards an object and attitude towards behaviour with 
respect to that object.  






Adapted from Fishbein & Ajzen (1975)  
As shown in figure 1 above, there are three determinants of behavioural intentions, 
namely the personal or attitudinal component and the social or normative component. 
Ajzen and Fishbein (1980) defined underlying beliefs (behavioural, normative, intentions 
and normative leading to behaviour and their measurement. Ajzen and Fishbein (1980) 
have shown that it is critical to have a high degree of correspondence between measures 
of attitude; norm, perceived control, intention, and behaviour. A change in any of these 
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2.10.2 Assumptions of the Theory of Reasoned Action  
According to Ajzen and Fishbein (1980),  the theory of reasoned action assumes that a 
person's behaviour is determined by his/her intention to perform the behaviour and that 
this intention is, in turn, a function of his/her attitude toward the behaviour and his/her 
subjective norm. The best predictor of behaviour is intention. Intention is the cognitive 
representation of a person's readiness to perform a given behaviour and it is considered 
the immediate precursor of behaviour. This intention is determined by three factors: their 
attitude toward the specific behaviour, their subjective norms and their perceived 
behavioural control. However, it is not clear that the TRA components are sufficient to 
predict behaviours in which volitional control is reduced (Ajzen, 1991). 
2.10.3 The Theory of Planned Behaviour (TPB) 
The Theory of Planned Behaviour (Ajzen, 1991), used to predict an array of behaviours 
including HIV clinical research is built further on the Theory of Reasoned Action 
(Werner, 2004). The TPB is determined by behavioural intentions which are largely 
influenced by an individual’s attitude toward behaviour and the subjective norms 
influencing the execution of the behaviour, and the individual’s perception of their 
control over the behaviour (Ajzen, 1991). The TPB adds perceived control over the 
behaviour, taking into account situations where one may not have complete volitional 
control over behavior (Smith et al., 2007 cited in Lutz, 2011).  
 For example, the perception of whether HIV prevention vaccine trial participation 












which it is viewed, that is, of the researcher or the trial participant. Whilst researchers 
recognize that trial participants have a crucial role to play in the development of an 
effective HIV prevention vaccine, this role primarily concerns a contribution to the 
scientific process. For the individual for whom the risk of HIV infection is constantly 
made salient, however, trial participation may appear to offer the direct benefit of 
protection from HIV infection.  






Adapted from Ajzen (1991) 
A person’s intentions are a good predictor of their behaviour. The stronger the intention 
to perform a particular behaviour, the more likely the person is to perform that behaviour. 
This, however, is not especially illuminating to say that people do what they intend to do 
is not particularly instructive. It is important to consider the determinants of behavioral 



















determinants, namely, beliefs, salient referents and perceived behavioral control (Ajzen, 
1988). 
2.10.4 Application of the Theories of Reasoned Action and Planned Behaviour 
Both TRA and TPB were designed to provide explanations of informational and 
motivational influences on behaviour and both models can be considered as deliberative 
processing models, as they imply that individuals make behavioural decisions based on 
careful consideration of available information (Conner & Armitage, 2001). Both models 
were designed to provide explanations of informational and motivational influences on 
behaviour. 
A study conducted by Sheeran and Orbell (1998), cit d in Rammule (2009) to examine 
the extent to which behavioural intentions are associated with condom use in 
heterosexual and gay men. A moderate relationship exists between intention and condom 
use behaviour. This suggests that intentions to use a condom do not always translate into 
condom use behaviour. Similarly, a finding was made by Bogart, Cecil and Pinkerton 
(2000) cited in Rammule (2009) in a study examining the use of female condoms among 
African-American adults. The only difference Bogart and colleagues found was that self-
efficacy in men showed a marginally significant relationship to intention to use a female 
condom with casual partners, but not with steady partners (Bogart et al., 2000 cited in 
Rammule, 2009). For both men and women, self-efficacy showed weak correlations with 
intention to use a female condom, and did not add to the explanatory power of the theory, 












men and women. For both men and women, self-efficacy showed weak correlations with 
intention to use a female condom, and did not add to the explanatory power of the theory. 
This finding suggests that self-efficacy may be a weaker predictor of female condom use 
for both men and women  
Although there seems to be exposure to some information in regard to HIV and AIDS, 
and how it can be prevented, it is also important to move towards behaviour change. As 
attitudes and beliefs have been shown to be significant in people’s choice of action, the 
theories of reasoned action and planned behaviour are relevant to behaviour change. The 
theory of reasoned action and the theory of planned behaviour were chosen for this study 
as they are the theories most cited in HIV and AIDS research, and have been found to be 
better analysts of HIV and AIDS health behavioural than other models (Fishbein, 1993; 
Warwick et al., 1993, cited in Rammule, 2009). 
The TRA and TPB have been applied in this study based on the assumption that if 
people’s attitudes towards specific HIV-preventive behaviours are shaped in particular 
directions and if their beliefs about the expectations of their significant others are 
reinforced, it is most likely that behaviour will change. Since attitudes and beliefs have 
proved to be significant in people’s choice of action, the researcher chose the theories of 
reasoned action and planned behaviour since they have been proved to be relevant to 
behaviour change.  
This study explored the perceptions and experiences of young people in participating in 












behaviour of interest in making decisions to participate in HIV vaccine trials. By 
applying the TRA and TPB theories to examine the correlates of trial participation, 
researchers may be afforded insights that offer more nuanced understandings and 
explanations that appropriately reflect and incorporate the complexities of HIV vaccine 
trial participation. 
2.10.5 Critique of the Theories of Reasoned Action and Planned Behaviour 
The theories of reasoned action and planned behaviour which fall within the realm of 
cognitive theories are based on the assumption that humans are endowed with the ability 
to reason, and that reason is the primary psychological process involved in decision-
making (Leviton, 1989 cited in Rammule, 2009). A major criticism of the TRA (which, 
in my view, should also apply to the TPB, since TPB is an extension of the TRA), is that 
its strong cognitive orientation tends to preclude the affective nature of humans, which 
also plays a role in decision-making pr cesses (Dutta-Bergman, 2005, cited in Rammule, 
2009). The Theory of Reasoned Action was criticized for neglecting the importance of 
social factors that in real life could be a determinant for individual behaviour (Werner, 
2004).  
Using sexual behaviour change as an example, the theory of reasoned action suggests that 
for behaviour change to occur, the individual must systematically identify and weigh the 
outcomes of his/her sexual behaviour to form attitudes towards the specific behaviour 
that must be learned. This assumes that behaviour change can be induced by adding a 












or decreasing the belief strength associated with the intended behaviour. While the 
individual may satisfy the requirements for behaviour change in this paradigm, they may 
not be able to enact the behaviour in a situation where they initiate sexual intercourse on 
the spur of the moment (Dutta-Bergman, 2005; Rammule, 2009). 
Another criticism is based on the focus of the theory of reasoned action on the individual 
as opposed to the group of which they are a member (Dutta-Bergman, 2005; Kashima, 
Gallois & McCamish, 1993, cited in Rammule, 2009)). This is particularly significant in 
HIV and AIDS research as Van Dyk (2001) cited in Rammule (2009) referring to the 
African context in which she writes, recommends that the community be involved in 
AIDS education, prevention and counselling. Emphasis is put on the significance of 
health care interventions in view of the collective existence that is a norm in traditional 
African contexts. The theory of reasoned action and the theory of planned behaviour, on 
the other hand, ignore the collective context in which individuals exist, and place 
emphasis solely on the individual actor (Van-Dyk, 2001, cited in Rammule, 2009)). 
Dutta-Bergman (2005) cited  in Rammule (2009) suggests that although proponents of 
the theory of reasoned action might argue that a subjective norm explains the role of the 
collective in an individual’s decision-making, it is still driven by an individual motive 
orientation, thus keeping the locus of decision-making with the individual. Although 
subjective norm taps into the individual actor’s evaluation of significant others, it does 
not tap into the complexity of the social fabric that constitutes the health behaviour in 












moves beyond the realm of a few significant others to the broader socio-cultural context 
of the community. Using the African collective context that Van-Dyk (2001) cited in 
Rammule (2009) referred to, it could happen that while the significant others closest to a 
person may discourage participation in HIV vaccine clinical trials the broader sub-culture 
to which a person belongs may consider such behaviour a norm. Such a strong emphasis 
on the individual ensures that the theory lacks a social-ecological approach that can be 
used to influence social policy. The social-ecological approach assumes that the 
community is super ordination to the individual, and transforming individual behaviour is 
therefore a consequence of transformation at a community level (Van-Dyk (2001), 2009 
cited in Rammule, 2009). 
The theory of planned behaviour holds that only specific attitudes toward the behaviour 
in question can be expected to predict that behaviour. In addition to measuring attitudes 
toward the behaviour, we also need t  measure people’s subjective norms and beliefs 
about how people they care abou  will view the behaviour in question (Fishbein & Ajzen, 
1975). 
Based on the above arguments, the researcher is of the view that TRA and TPB cannot 
themselves be used to address questions relating to how beliefs and attitudes 
underpinning behavioural intentions can be changed. The sufficiency of the TRA and the 
TPB has been questioned and thus suggestions made for an extension of these theories 
because the variables of attitude, subjective norm and perceived behavioural control may 














Chapter three presents the research setting, research design; population and sample, 
piloting the study; data collection; data analysis; data apparatus, data verification, ethical 
considerations, reflexivity and limitations of the study.  
Research methodology focuses on the research process, tools, and objective procedures to 
be undertaken, as well as specific tasks to be used (Babbie & Mouton, 2001). Included 
research design is the approach, type and purpose of the research. The methodology 
discussed the sampling procedures, data collection methods, tools and data analysis.  
3.1 Research Design 
Mouton & Marais (1993) cited in De Vos (2011) define a research design as a plan or 
blue print of the study. This plan includes who, what, where, when and the how of the 
topic under study. The research design is a guideline on which a choice of data collection 
methods can be made. For the purpose of this study, the researcher will follow an 
exploratory design approach and explore the perceptions and experiences of young 
women about HIV prevention vaccine clinical trials.  
This design is considered useful when the researcher has limited knowledge about the 
subject.  Fouche & Delport (2002) cited in De Vos (2011) explain how qualitative 
research helps the researcher make use of multiple methods such as interviews and 
observations in to understand the context of what is being researched. More to that 












to the phenomenon under investigation. Qualitative approach will allow the researcher to 
explore the circumstances and perceptions that the young people have towards 
participating in HIV prevention vaccine clinical trials (Fouche & Delport, 2002 cited in 
De Vos, 2011) 
3.2 The Research Setting 
To gain further insight into the study, focus area reference was made to Statistics South 
Africa (StatSA), (2011) Census data, to examine the basic socio-economic data of the 
township. The population is predominantly Black African (99%), 31% of those aged 20 
years and older has completed Grade 12 or higher. 55% of the labour force (aged 15 to 
64) is employed and 74% households have a monthly income of R3 200 or less. 67% of 
households live in formal dwellings, 79% of households have access to piped water in 
their dwelling. 81% of households have access to a flush toilet connected to the public 
sewer system, 92% of households have their refuse removed at least once a week, and 
95% of households use electricity for lighting in their dwelling (StatSA, 2011). 
According to South African History, Nyanga Township is one of the oldest and largest 
black townships. It lies about 26 kilometers from the city centre, along the N2 close to the 
Cape Town International Airport. Like most of townships in the country, Nyanga 
originated as a result of the migrant labour system (Marais, 1998). The United Nation’s 
Development Index Report (2010) explains that in Nyanga HIV prevalence rates tend to 












to the poor and the persistent set of economic and spatial dynamics has helped to fuel 
HIV in the township (Hunter, 2006). 
3.3 Population and Sample 
A population is defined as the totality of all subjects that conform to a set of 
specifications, comprising the entire group of persons that are of interest to the researcher 
and to whom the research results can be generalized (Polit & Hungler, 1999). A sample is 
a sub-set to of a population selected to participate in a study (Polit & Hungler, 1999). The 
population sampled consisted of young women between the ages of 18-24 years, some of 
whom were also participants in on-going vaccine studies. Also included in the population 
sample were key informant participants either from the Nyanga township communities or 
from community based organization, Non-governmental organization (NGOs) and staff 
from local clinics. 
3.3.1 Sampling Procedure 
A purposive sample of 27 participants was interviewed. These include young women 
who are participants in the ongoing clinical trials, women or are not participating/have 
not participated in HIV prevention vaccine clinical trials, plus five other participants 
either from community-based organizations or from the wider Nyanga Township 
community. The research purposively targeted fifty five respondents but eventually a 
total sum of twenty seven was interviewed. When using this type of sampling, the sample 
is mostly selected on ease of access and is based on the judgment of the researcher (De 












knowledge about the study topic and they are important to the research topic. The 
sampling method used in this study was purposeful sampling. This is because purposeful 
sampling seeks information which can be studied in-depth (De Vos, 2001).  
The eligibility criteria used in this study include: 
 Young women who are participants in the on-going clinical trials; 
 Women or are not participating/have not participated in HIV prevention vaccine 
clinical trials; 
 Representatives from the community-based research organization; 
 Representatives from community based NGOs;  
 Representatives from the local clinic, and who were willing to participate in the 
study; 
 Participants from the wider community; and 
 One student from the community school 
Eligibility criteria are specifications used by the researcher that designate the specific 
attributes of the target population determining which subjects are selected to participate 
in a study (Polit & Hungler, 1999). The inclusion criteria used in this study was people 












According to De Vos (2011), the most useful strategy for the naturalistic approach is 
maximum variation sampling. This strategy aims at capturing and describing the central 
themes or principal outcomes that cut across a great deal of participant or program 
variation (Lincoln & Guba, 1985, cited in De Vos, 2011). 
3.3.2 Recruitment of Participants 
Recruitment of study participants was done using convenience sampling. The researcher 
identified participants by approaching young women who are currently enrolled in 
vaccine trials and have designated visit schedules for their clinic visits. Before 
identification of participants the researcher sought permission from the site manager to 
conduct this study. The same method was applied while identifying subjects from the 
wider community by seeking permission from community leaders and leaders in other 
community-based NGOs. Efforts were made by the researcher to interview young women 
in the ages of 18-24 years. Some young men were interviewed to ensure that all 
categories that are either directly or indirectly involved in participating in HIV vaccine 
trials were represented.  
3.3.3 Pre-testing of the Interview Guide 
Pre-test is a trial run to determine, as far as possible, the clarity, adequacy and freedom 
from bias of the research. Pre-test was done with individuals who have similar 
characteristics with those who were to be interviewed in the study (Polit & Hungler, 
1999). A draft interview guide was discussed with my supervisor who is knowledgeable 












This was done to ensure that all important steps and details have been taken care of 
before pre-testing is done. The final draft was then pre-tested among young women who 
meet the set eligibility criteria. The pretested participants were not to participate in the 
main research study because of the concern that they would have already been exposed to 
an intervention and therefore may respond differently from those who were previously 
not exposed.  
3.4 Data Collection 
In this section data collection strategies have been discussed. 
3.4.1 Data Collection Approach 
To obtain information from participants, the researcher used a semi-structured interview 
schedule to collect data from participants. The participants comprised of young women 
aged 18-24 years (See Table 1). The advantage of a semi-structured interview schedule is 
that it can be pretested on a suitable participant and also allows the researcher to refine 
the wording, ordering and layout of the questions (De Vos et al., 2011). Interviewing is 
the predominant mode of data collection in qualitative research (De Vos, 2011). The 
researcher chose the above-mentioned approach because it facilitates interaction between 
the researcher and the participants and also enables the researcher to gain a detailed 
picture of the participant’s beliefs, perceptions and accounts of a particular topic under 














3.4.2 Data Collection Apparatus 
Before interviews were conducted, the researcher first explained to the participants that 
she was going to use unstructured interview guide and also sought permission to record 
the interview (De Vos, 2011). The study used a tape recorder to record the interviews as 
it allows the researcher to concentrate on exploring the topic while also noting the non-
verbal cues. The tape recorder was preferred because it allows for verbatim recording 
hence facilitating more accurate data collection and analysis (Saunders & Thornhill, 2003 
cited in De Vos 2011). Smith et al., (1995) cited in De Vos (2011) mention that a tape 
recorded allows a much fuller record than notes taken during the interview. It also means 
that the researcher can concentrate on how the interview is proceeding while following 
up interesting points being made, prompting and probing where necessary, drawing and 
paying attention to any inconsistencies in the interviewee’s responses. Care was taken so 
that the voice recorder was modest during the interview in order to avoid unnerving the 
participant and the researcher (De Vos et al., 2001). 
3.5 Data Analysis and Verification 
Data analysis is the process of bringing order, structure and meaning to the mass of 
collected data (De Vos, 2011). Data analysis is the activity of making sense of, 
interpreting and theorizing data (Schwandt 2007cited in De Vos 2011). Gibbs (2007) 
cited in De Vos (2011) states that the idea of analysis implies some kind of 
transformation. One starts with some (often voluminous) collection of qualitative data 
and then processes it, through analytic procedures, into a clear, understandable, 












Using the data collected through interviews, the researcher transcribed the data from the 
tape recorder and written notes, and an adaptation of Tesch (1990) cited in De Vos (2011) 
steps were as outlined below:  
 The researcher read through all the transcriptions and then selected one interview 
at a time, tried to understand what the respondent was saying in relation to the 
objectives of the research 
 The researcher jotted down some words (phrases) on the margins that capture the 
participants’ meaning/perceptions. In the margin of the transcript, the researcher 
assigned labels to those meanings; 
 All the transcriptions were subjected to the process of assigning labels; 
 The researcher then grouped the labels into categories of the main themes; 
 The researcher then revisited the main themes and categories in order to make 
sure that these themes and categories encapsulated the fullness of the data. All 
categories had sub-categories; 
 The categories were reworked to make sure that they are mutually exclusive; 
 A coding framework was developed; 
 The findings were written up using the coding framework as a guide. Actual 
quotes were used to illustrate the themes/categories and for subcategories/sub-












review) thereby validating or contradicting the findings; and developed critical 
arguments 
3.5.1 Data Verification 
The researcher verified the collected data using Guba’s approach (Lincoln & Guba cited 
in De Vos, 2001). This was aimed at ensuring accountability to ward off biases and errors 
in the results of a qualitative data analysis. The four constructs central to this approach 
include credibility, transferability, dependability and confirmability (De Vos, 2001).  
 Credibility demonstrates that the study was conducted in such a manner as to ensure 
that the phenomenon is accurately described.  
 Transferability is the burden of demonstrating the applicability of one set of findings 
to another context.  
 Dependability is any attempt to account for reliability of the study; and 
 Conformability focuses on whether the results of the study could be confirmed by 
another (De Vos, 2001).  
3.6 Ethical Considerations  
When conducting research, there are ethical guidelines that should be followed. Ethics is 
typically associated with morality as it deals with matters of right and wrong. In social 
research, there are general agreements among researchers about what is proper and 












Ethics is defined as a set of moral principles which is suggested by an individual or group 
is, subsequently widely accepted, and which offers rules and behavioural expectations 
about the most correct conduct towards experimental subjects and respondents, 
employers, sponsors, other researchers, assistants and students (De Vos, 2011). Anyone 
in research needs to be aware of the general agreement about what is proper and 
Improper in scientific research (Babbie 2001, cited in De Vos, 2011).  Based on this fact, 
researchers need to ensure that the rights of study subjects are safeguarded. In this study, 
ethical issues were taken into consideration especially realizing that HIV clinical trials is 
a sensitive issue and that HIV is a human rights issue.  
In carrying out the study, the researcher was bound by the following ethical issues as 
outlined by De Vos (2011) and Babbie and Mouton (2007). 
3.6.1 Informed Consent 
Before interviews were conducted, the researcher obtained informed consent from the 
participants based on the rights to self-determination to participate in the study (Appendix 
1). In this study, the researcher informed the participants about the purpose, potential 
benefits, pledge for confidentiality, right to withdraw and that participation was 
voluntary. Informed consent form contains information about the goal of the study, 
procedures that are to be followed during the study, the possible advantages, and 
disadvantages and credibility of the researcher (De Vos, 2011). The informed consent 












they agree to participate and also to know the advantages and disadvantages and dangers 
that they may be exposed to as a result of their participation. 
3.6.2 Human Subjects’ Protection  
In order to protect participants the researcher obtained ethical approval from the 
University of Cape Town, Department of Social Development. This was aimed at 
protecting participants from harm, exploitation and knowledge of potential benefits. This 
principle encompasses the maxim of above all do not harm (Polit & Hungler, 1999). The 
researcher included these dimensions to ensure that the participants know the benefits of 
the study and have full details about the study as well as pr viding a clear explanation 
regarding the purpose, objectives as well as the potential benefits of the study without 
raising any unrealistic expectations. 
3.6.3 Confidentiality and Anonymity 
Confidentiality means that no information that the participant divulges is made public or 
available to others and the anonymity of a person or an institution is protected by making 
it impossible to link aspects of data to a specific person or institution (Polit & Hungler, 
1999). In this study, the researcher guaranteed confidentiality and anonymity assuring 
participants that the data obtained from them will be used in such a way that no one other 
than the researcher knows the source. The researcher ensured that information collected 
from the study participants was not divulged or publicly reported and that no the 
participants’ identifiers would be attached to the data provided. The researcher also 












protected to avoid access by ‘outsiders’ and that all documents containing raw data will 
be destroyed after the dissertation has been accepted by the university. 
3.6.4 Privacy 
According to De Vos (2011), privacy in its most basic meaning refers to keeping to 
oneself that which is normally not intended for others to observe or analyze. The 
researcher maintained privacy in this study by conducting interviews in private and 
secure places where nobody else could have access except the researcher herself. The 
right to privacy was also respected in this by ensuring that no intrusion is made during 
interviews with participants.  
3.6.5 Rights and Benefits to the Participants 
The protection of the rights of the participants w s a priority in this study. The researcher 
informed the participants about the purpose of the study (Appendix I). The researcher 
informed participants that their participation was voluntary and that they could choose to 
discontinue participating at any point should they wish to without incurring ill effects 
whatsoever. This was meant to ensure the participants’ rights to self-determination and 
full disclosure. The right to self-determinations means that participants have the right to 
voluntary decide whether to or not participate in the study without incurring penalties or 
the risk of prejudicial judgment (Polit & Hungler, 1999). Benefits to participants include 















The researcher ensured to incorporate a debriefing section after the interview. Debriefing 
is a session after the study in which participants get the opportunity to work through their 
experience of the study and its aftermath (De Vos, 2011). Debriefing interviews 
encourage the researcher to monitor the degree to which participants and stakeholders are 
empowered to act on the increased understanding that emerged from the study 
(Onwuegbuzie et al., 2008). It constitutes one possible way in which the researcher can 
assist participants and minimize harm. In this section, the researcher asked participants to 
talk about their feelings of doing the interviews and if they had encountered any problems 
in taking part in the study thereof. This session was meant to help the researcher rectify 
any misconceptions that may have arisen in the minds of participants. The researcher 
conducted debriefing interviews in a private place and these were tape recorded. The 
session helped the researcher get to understand concerns regarding the impact of the 
study on the participants and also to establish if any, problems that could have stemmed 
from the interviews.  
3.7 Limitations of the Study 
Limitations in research are those aspects that may negatively influence the results but 
over which the researcher has no control (Mugenda & Mugenda, 1999). Various 
limitations were encountered during the study and these are related to the research design, 













The qualitative research design is highly subjective in nature and the sampling technique 
of non-probability sampling used is generally small and cannot be generalized to a larger 
population (Mugenda and Mugenda, 1999; De Vos, 2007). Because the researcher used 
semi-structured interviews there is a possibility that inferences were made based on her 
subjective experiences. The researcher overcame this limitation by ‘bracketing’ her own 
feelings.  Nevertheless, the researcher found this design appropriate to explore the 
perceptions and experiences of participants in HIV prevention vaccine clinical trials in 
order to gain a deeper understanding of the meaning participants gave to their situation.  
The research used a semi-structured interview schedule. The use of a semi-structured 
interview schedule can be misused as a novice researcher could stick too rigidly and not 
allow for the free flow of communication. However, the researcher was aware of this and 
tried to allow for maximum information through probing.  
The use of a tape recorder to capture data made it likely for some participants to be 
reluctant to give information as they knew they were being taped and some participants 
declined to be tape recorded. However, the researcher used the tape recorder for most 
participants who consented to it since verbatim recordings allow for all the verbal details 
to be captured and analyzed (Saunders & Thornhill, 2003 cited in De Vos, 2011). In this 
study, some participants declined to be tape-recorded because they felt that nobody else 
should hear them talk about the HIV related issues.  In that case the researcher resorted to 












research since the researcher may not have written everything down during the 
interviews.  
An adaptation of Tesch (1990) cited in De Vos (2011) used to analyze data requires the 
researcher to identify themes and categories. Since procedure allows the data to be 
analyzed in a subjective manner, it may be wrongly interpreted and biased as some 
categories may be either overlooked or overemphasized. As a result, this can affect the 
accuracy of the research findings. Nevertheless, the approach was used as it allows data 
to be analyzed using empathetic understanding to make sense and to draw meaningful 
conclusions (Mugenda & Mugenda, 1999).  
Some participants felt comfortable speaking in th ir local language but since the 
researcher is not well-conversant with the Xhosa language which the majority of the 
participants speak. , she resorted to those participants that understand and speak English. 
As a result the chosen sample had a language bias. Nonetheless, the researcher chose 


















PRESENTATION AND DISCUSSION OF FINDINGS 
This chapter presents findings from the interviews following a comparison and an 
analysis of findings from literature review. The chapter is structured as follows: 
demographics of participants, framework of analysis and a discussion of the findings 
from the interviews using a framework of analysis. The research findings are divided into 
themes, categories, and subcategories adopted from Tesch (2011).  
4.1 Introduction 
The aim of the research was to explore the perceptions and experiences of young women 
on their participation in HIV vaccine clinical trials in Nyanga. The study followed a 
qualitative research design in explorative and descriptive nature. The study anticipated to 
use in-depth interviews with 33 respondents, but ended up getting only 27 because some 
of these were either not available or too busy to participate in the interview. Findings 
have been summarized in the last section of this chapter. 
4.2 Socio-Demographics Characteristics of Participants 
This section provides a profile of participants and this gives the background information 
of the participants in terms of demographic categories. The profile is categorized 
according to education level and employment status.  Also explained are sex, race, family 













Table 1 below presents the demographic profile of main study participants that comprises 
of 12 young women, all between the ages of 18-24.  





Education  Employment status 
Primary  Matric  Employed  unemployed 
12 0 2 10 
 
The participants chosen were from various backgrounds and they range between the ages 
of 18-24 years. All the participants in this study do not have matric certificates. Ten of 
the participants out of twelve were unemployed, which reflects the state of youth 




















4.2.1 Key Informants’ Profile 
Table 2 below presents key informants’ profile.  
Table 2: Key Informants’ Profiles 
Category  Number  Description  
HIV research-based 
organization centre 
4 These organizations conduct projects that support HIV 
positive youth, provide clinical support to HIV positive 
counselors, conduct community outreach to vulnerable groups 
such as men who have sex with men, provide anti-retroviral 
services to the vulnerable communities, HIV Mobile testing 
services and conduct HIV prevention clinical trials 
Community based 
Organizations 
3 Advocacy for increased access to treatment, care and support 
services for people living with HIV and campaigns to reduce 
new HIV infections; advocates of human rights, gender 
equality and equity; and creating HIV awareness and support 
to HIV positive women 




2 The CAB provides the opportunity for community to 
understand clinical research and purposes. It is the forum to 
voice concerns regarding specific clinical studies, their 
development, implementation and outcome 
Community members 4 From the Nyanga township 
Students  1 Scholar from the community school 













The 15 key informant participants interviewed include 4 representatives from a research 
based organization, 2 Community Advisory Board (CAB) members, 3 from Community 
Based Organization (CBOs), 1 student, 1 participant from the local clinic and 4 
community members. It should also be noted that due to issues around privacy 1 
participant from a CBO and 1 research participant declined to be tape recorded hence the 
researcher had to take notes. 
4.3 Framework for Discussion of Findings 
In order to identify themes and categories, the researcher used an adaptation of Tesch 
(1990) cited in De Vos (2011) and reference made to Chapter Three, Section 3.7 of 
Tesch’s Approach to Analysis. Identified were nine major themes linked to the research 
objectives and thirty two categories. The categories of these themes emerged from an 


















Table 3: Framework for discussion of research findings 
Themes  Categories  
Motivations to participate in clinical 
trials 
 
 Protection from HIV 
 Financial incentives 
 Free medical care and treatment 
 Altruism 
 Receiving information about HIV 
Perceptions and experiences about 
clinical trials 
 Vaccines good for the community 
 Vaccines make people sick 
 Inadequate knowledge about vaccines 
 Community perceptions and 
misconceptions about vaccines 
Attitudes towards participation  Mistrust of researchers 
 Safety of the vaccine 
 Vulnerability of getting infected 
 Inadequate knowledge about scientific 
concepts 
Subjective norms to participation  Behavioural beliefs 
 Normative beliefs 
 Motivation to comply  
Risks   Potential physiological risks  
 Potential psychosocial risks 
Barriers   Vaccination side effects 
 Sero-positivity due to vaccine 
inducement 












 Perceived risk of HIV infection from 
the vaccine 
Challenges and barriers  Time commitments to attending study 
visits 
 Stigmatization and discrimination 
 Community misconception that the 
vaccine contain an HIV virus 
 Being afraid of needles 
 Perception that some people may 
never be affected or infected by HIV 
Benefits   Improved knowledge on HIV 
 Access to health services 
 Financial benefits 
Rights   Right to participate or decline to 
participate 
Knowledge of policies and legal 
framework 
 Inadequate knowledge about HIV 
vaccine related policies 
 
The findings will be discussed logically as presented in the framework above. 
4.4 Motivating factors for Participation in HIV Clinical Trials 
The findings in this section are linked to the first research objective which investigated 
the reasons which motivate young women to participate in HIV prevention clinical trials. 














4.4.1 Protection from HIV 
Most participants indicated that the most important reason they participated in HIV 
vaccine clinical trials is because they wanted to be protected from getting infected with 
HIV, as illustrated below: 
Yah, yah, but my boyfriend says as long as it is for HIV 
prevention he does not mind me taking part… [22 year old 
vaccine trial participant] 
Some participants were hopeful that if the cure for HIV is found, then the world will be 
safe from dying from  HIV and AIDS but add that some people in the community are sure 
that vaccine trials are a real cure for HIV as illustrated below: 
It gives me hope that one day HIV will be a forgotten thing; 
but they said it being tried to see if it works – I think some 
of my friends think they are safe and protected with the 
vaccine. Some of them do not use condoms with their 
boyfriends because they are protected [18 year old vaccine 
trial participant]. 
Some participants had a mixed range of arguments for joining the trials. Among them is 
getting money, getting free medical care and getting protection from HIV, as evidenced 
from the following remarks: 
I joined because my friend also said if you get the vaccine 
injection you get protection from HIV infection and get 
paid at the clinic … [19 year old vaccine trial participant] 
Protection from HIV as a motivator may be a consequence of high perceived risk of 
acquiring HIV and based on this argument, desire for protection as a motivator would 
need to be addressed in a clinical trial. The vaccine may be protective, enhance the risk of 












According to some participants’ responses there seems to be an enhancement of 
behaviour since there is a perceived belief that the vaccine can protect them from 
contracting HIV. 
4.4.2  Financial Incentive Gains 
Almost all participants confessed that their willingness to volunteers in HIV prevention 
vaccine clinical trials was because of the monetary reimbursements provided to them at 
the research centre. Most young women participants reported to have children and they 
are single mothers who are unemployed. By participating in HIV vaccine clinical trials, 
they expect money in return for their participation. Participants’ explanations in regard to 
monetary incentives are as explained below:  
I am unemployed and life becomes very hard but now I am 
assured of money at every visit; I heard of the bad things 
about vaccines but I have no choice … [22 year old vaccine 
trials participant] 
Another participant adds: 
… this money helps me to buy food for my child … [20 
year old vaccine trials participant] 
This participant appreciates the fact that they get re-imbursed for their transport fare, a 
rare opportunity not found in the local clinics as she expresses herself below: 
…in the local clinic nobody gives money for the transport 
used meanwhile here I get money for my transport … [20 
year old vaccine trial participant] 
Similar concerns about the role of financial incentives as a stimulant to participate in HIV 
vaccine clinical trials were expressed in studies conducted in other low-and middle-












of America. Findings reveal that many men who have sex with men (MSMs) expressed 
willingness to participate based on contingent on clinical trials providing health insurance 
coverage and financial compensation for family members in the event they are injured in 
a trial (Moodley, et al., 2002). 
Most participants are unemployed, so getting a financial incentive boosts their financial 
income and facilitates access to basic life requirements. However, as regards monetary 
incentives, some people have varying perceptions about participants being paid. Some 
participants expressed their concerns as follows: 
People in the community asked me why I get paid if the 
vaccine is meant to help get a cure for HIV [22 year old 
vaccine trial participant] 
Some participants had a feeling that clinical trials are good because they are trying to find 
a cure against HIV but they are not happy about how they are introduced in poor 
communities. The choice of trial sites leaves some people to be suspicious as illustrated 
here below: 
I think there is something good in it but I wonder why in 
Cape Town the trials are conducted in only black 
communities – is it because we are black or poor so we 
cannot question anything…  [Key informant, local clinic] 
Bearing in mind the complex past of South Africa and especially black South Africans, 
such socially derived fears and frustrations can easily be seen as underlying reasons 
behind the participants’ fears and concerns regarding the choice of HIV vaccine clinical 
trial sites. Responses from participants coincide with media reports which made the 












with HIV in order to wipe out the African people (McGreal, 2007). Taylor (2012) reports 
condoms infected with HIV also aimed at killing the blacks.   
4.4.3 Access to Medical Care and Treatment 
Almost all participants confessed that participating in HIV prevention vaccine clinical 
enabled them to access free medical care. Below are some of the illustrations about the 
health situation:  
I wanted to know my health condition. Here at the centre 
they check everything in the body … for free [19 year old 
vaccine trial participant] 
Relatedly, the other participants were attracted to medical care and attention offered at 
the vaccine centre as explained here under: 
I get free medical check-ups and knowing my HIV status… 
[19 year old vaccine trial participant] 
Similarly this participant was appreciative of the of health gains from the researcher 
centre, as explained below: 
Until I joined this research centre I had never had a full 
health scr ening. It involves a lot of money to get this done 
in a pri ate clinic… [20 year old vaccine trial participant] 
One key informant also reiterated that researchers have given women preference because 
they are the most affected and infected with HIV than men as illustrated below:  
We at this facility focus on women because they are the 
most affected. In our communities not much has been done 
for women in terms of primary health care; when they come 














Similar concerns about the role of financial incentives as a stimulant to participate in HIV 
vaccine clinical trials were expressed in studies conducted in other low-and middle-
income country sites in Africa and among marginalized populations in the United States 
of America. Findings reveal that many men who have sex with men (MSMs) expressed 
willingness to participate based on contingent on clinical trials providing health insurance 
coverage and financial compensation for family members in the event they are injured in 
a trial (Moodley, et al., 2002). 
4.4.4 Altruism towards community wellness 
Some participants indicated that they volunteered to participate for the sake of those who 
are vulnerable to getting infected in their communities and also being part of the global 
campaign against the killer disease. This is manifested in the responses illustrated below: 
 I feel good to be part of the study; I want to make a 
difference in other people’s lives [22 year old vaccine trial 
participant]. 
The desire to help find prevention as well as a cure for HIV has driven some participants 
into the vaccine trials: 
I just wanted to be part of the research work; and if they 
find a cure for HIV I will be among the heroes who gave 















Some participants have lost their loved ones and now feel it is time they contributed 
towards finding a cure for HIV: 
I remember my cousin who died of HIV if 
prevention had been in existence she would 
not have contracted HIV… [18 year old 
vaccine trials participant] 
For some participants they do not have a specific reason but just to be part of the studies: 
I just wanted to be part of the research work 
[23 year old vaccine trial participant] 
These above statements were reiterated by key informant from an HIV vaccine centre: 
According to my recollection and observation, these young 
people are brave, full of enthusiasm… families need their 
support; most families been affected by losing loved ones; 
they want to see HIV come to an end; … [key participant 
from a vaccine trial centre] 
The above responses collaborate with findings from which identified altruism as a 
common motivator for clinical trial participation. The studies indicate that some people 
participate in HIV vaccine clinical trials to make a contribution towards the fight against 
HIV and AIDS (Sahay, et al., 2005). According to the voices of the young people in this 
study, they seem to be optimistic that the future lies in their hands so their contribution as 
clinical trial participants is of paramount importance.  
4.4.5 Receive Information about HIV  
Almost all participants were happy about health education they receive on HIV as being 












All clinical trial participants agreed that whenever they attend their study visits risk 
reduction counselling is reinforced as a reminder to them to practice safe sex.    
I think this routine counselling is good. I 
used to sleep with my boyfriends without 
minding about using condoms but now I 
insist on using a condom [20 year old 
vaccine trial participant] 
Another participant stated: 
… you get reminded of risky behaviour that can put you at 
risk of getting HIV [19 year old vaccine trial participant] 
Some participants seemed not to be sure of issues around HIV and vaccine trials so to 
them it was an opportunity to gain clear understanding as explained below: 
I wanted to get more knowledge about HIV 
… [24 year old vaccine trial participant] 
Some other participants who are not enrolled on clinical trial volunteers yearn to get 
information about vaccines because of what they hear in the communities about vaccines: 
I hear they give women things to protect 
them from HIV but I do not know whether it 
is true [community member] 
One key informant from a vaccine centre listed a number of services offered at the clinic 
to include the following: talks about diet, exercise, Family planning, where she insists 
participants have limited knowledge about clinical trials so health education provided to 
them is meant to empower the vulnerable township young women. 
Potential trial participants should be made to understand that the effectiveness of the HIV 
vaccine to be tested is not known. Based on required ethical considerations in HIV 












counselling, HIV testing, male and female condoms, and treatment for sexually 
transmitted infections. Nonetheless, not all participants seemed to agree that the idea of 
risk reduction was easily applicable.  
One young woman expressed her fear that as sex worker she may not decide when a 
condom should be used with a male client as explains here below: 
How can I use condoms regularly when my 
clients demand that if I am to be paid some 
‘good’ money they decide either to use 
condoms or not because he is paying for a 
service [19 year old vaccine trial 
participant].  
Women’s ability to control their sex lives has been discussed by Kahn (2005) who argued 
that lack of economic power for women make them vulnerable to accepting certain 
conditions that may jeopardize their health. For instance, it is common to find a woman 
who may willingly continue living with a man whose behaviour puts her at risk on HIV 
infection for the sake of financial dependence. 
The study participants shared with the researcher the social, economic and cultural issues 
and possibly faced risks of HIV infection. Yet, in contradiction, their statements 
concerning HIV and AIDS and sexual relationships with men were typical and reflected a 
greater sense of individual agency. Based on their arguments, the study participant in 
HIV vaccine trials appeared more knowledgeable about the possibilities of contracting 
HIV and this was attributed to the fact that these participants had acquired some relevant 
information and knowledge during their clinic visit and they seemed empowered to make 












Below are some of their views: 
After testing and knowing my HIV status (negative) I have 
vowed never to get involved in risky behaviour [19 year old 
vaccine trial participant] 
Another participant adds: 
My partner and I have now stuck together … and now using 
condoms always, thanks to the study counsellors”, [24 year 
old vaccine trial participant] 
This is an indication that participation in the HIV prevention vaccine trial procedures and 
in particular the regular HIV counselling and testing is informative and transformative. 
According to the medical ethical guidelines, efforts must be made to maximise the 
potential benefits of HIV preventive vaccine research. he research protocol should 
outline the benefits that participants in HIV vaccine trials should receive as a result of 
their participation and ensure that the risks undertaken by the participants from that 
population should be balanced by the potential benefits (Slack and Kruger, 2003). 
4.5 Perceptions in participating in HIV Prevention Vaccine Clinical Trials 
How women and men perceive their participation in HIV vaccine prevention clinical 
trials is an important issue for HIV prevention trial research and an important component 
of study design. However, reports show that  in South Africa, HIV is perceived as a 
‘black disease’, due in part to popular media representations of AIDS, that project an 
image of HIV and AIDS as young, black, and female (McNeil and Donald,1999). 
Furthermore, women who reside in South African Townships are faced with socio-
economic and cultural challenges. Some of these challenges include sexual violence and 












study participants in this study cited social, economic and cultural environment as some 
of the contributing factors to the possible increase of their vulnerability to HIV infection.  
Participants’ perceptions vary. Most of the participants described the comprehension of 
the study procedures as being fairly good while some of the participants expressed 
considerable anxieties about the procedures. 
4.5.1 Vaccines are good for the Community and the World 
Participants who expressed satisfaction regarding their participation in vaccine clinical 
trials pointed out their appreciation regarding clinic procedures such as the regular pap 
smears for cervical cancer, the screening for sexually transmitted diseases (STIs), 
counselling and HIV testing, information given about HIV and AIDS. To some 
participants, vaccines give them hope of prevention from being infected with HIV. And 
most importantly there is hope that if vaccines are found to be effective, then their 
children will have an HIV free future world. Additionally, participants were reimbursed 
for their time and travel and to most of them the reimbursement is entirely their source of 
income for the general household consumption given the socio-economic situation of 
most trial participants who are unemployed and hence have no source of income.   
Most importantly, majority of the participants mentioned that the vaccine centre was the 
only place where they had been treated with dignity and respect unlike the public health 













Responses from almost all participants indicated, as explained by some of the 
participants: 
It is a good thing, for sure if what they 
[study staff] told me is correct then there is 
hope for discovering a cure for HIV … [19 
year old vaccine trial participant] 
Another participant had similar views as stated below: 
It is a good thing, I support the idea. People 
have died of HIV it is high time a cure is 
found to stop this dreadful killer of our 
young people!! [22 year old, vaccine trial 
participant] 
A representative from community NGOs also emphasized that vaccine trials are for the 
good cause as explained below: 
People in our communities have responded to the call to fight the 
dreaded disease and that is the reason why you see mostly young 
women flocking to the research centre... [Key informant, community 
NGO] 
As one of the routine processes all young women participants mentioned that it was 
mandatory for them to go through Voluntary Counselling and Testing (VCT) a process 
that came with mixed feelings. Participants revealed they had gained knowledge 
regarding their sexual and reproductive health. This is true given the fact that the 
researchers emphasize  that all young people who are legible and accept to participate and 
in HIV vaccine prevention clinical trials are obliged to go through a range of medical 
examination and treatment STIs, HIV testing and condom counselling and use and 
adherence. The HIV test and its influence on how enrolled women felt about their current 












study participants.  A clinical trial participant narrated how having tested for STIs and 
HIV had had a significant impact on her sexual behaviour. She emphasized her 
commitment to using condoms always, in order to avoid infection.  
The following quotation explains a young women study participant’s response to sexual 
behavioural change:  
I used to have multiple partners but now I have changed and I now 
know which friends I hang out with…. I tell you what: before I did not 
know my status I for sure did not really care who to go out (sleep) 
with... [18 year old clinical trial participant] 
Some participants acknowledged that risk reduction counseling has helped them shape 
not only their own sexual behaviour but also for their partners as illustrated below:  
… I decided to join the vaccine clinical trials because I 
wanted to know my HIV my status. I have since stuck to my 
main boyfriend who I have also convinced to use condoms 
always [22 year old vaccine trial participant] 
The mere fact that this particular not only talk of using condoms but also of being 
committed to a monogamous relationship with emphasis to use condoms always is 
regarded by the clinical researchers as a resource that she draws on to reaffirm her 
commitment to avoid being exposed to HIV.  The study participants not only give 
attention to HIV infection, but also the importance of knowing one's status, regardless of 
the outcome.  
This particular participant who openly testified to be living with HIV also had a relatively 












The thing that makes me return to the clinic is that my eyes 
are now open. It is correct to know your status… [18 year 
old vaccine trial participant] 
Participants’ commentaries about their involvement in HIV prevention vaccine clinical 
trials seems to reflect the emergence of a powerful discourse that stresses their need to 
take control over the circumstances and relationships that may place them at risk of being 
infected with HIV. 
4.6 Experiences in participating in HIV Vaccine Clinical Trials 
Participants have different opinions and experiences about their participation in HIV 
vaccine clinical trials. Some participants expressed positive views about the vaccine 
trials, while others had negative thinking. 
4.6.1 Vaccines are good for the community 
Some participants appreciated HIV prevention vaccines because as the word ‘prevention’ 
is used they assume that they prevent them from getting infected with HIV. Below are 
some of the responses: 
I am now happy that I and my boyfriend can 
stop using condoms because of the 
protection by the vaccine [20 year old 
vaccine trial study participant] 
Another participant adds: 
…I was told that I would get family 
planning services, and also the “protection” 














This particular participant feels good to be a participant but has made some observations 
especially about her friends’ behavioural change as she explains here under: 
I have realized that this vaccine has made some of my 
friends change their life styles. Girls are now saying that 
there is no use for condoms after being injected [vaccinated] 
with a vaccine which protects them from getting infected 
with HIV. They want to try and ‘see’ if it works… [22 year 
old, vaccine trial participant] 
Overall, participants’ experiences in HIV vaccine trial seem to involve multiple factors. 
These factors could have important implications for promotion of participation in HIV 
prevention vaccine clinical trials. 
4.6.2 Vaccines are not Good for the Community 
Some had bad experiences and while others expressed mixed feelings and uncertainties 
about HIV vaccine clinical trials, some of which portray a negative picture. Some 
participants think vaccines cause sickness as illustrated here below: 
My first experience was not good, after being vaccinated I 
went home feeling weak, dizzy and nauseas …[19 year old 
vaccine trial participant] 
Another participant explained how she got sick after vaccination: 
… Every time I get an injection I fall sick of headache, joint 
pains and last month. I had virginal bleeding for almost two 
weeks. This made me worried and up to now I do not feel 
well. But I was given a letter which I took to the local clinic 













Some participants have a feeling that researchers are using them as guinea pig to test 
strange medications that have not yet been tested on humans. Some of the illustrations 
manifest such feelings: 
To be honest this vaccine ‘thing’ is quite 
new and not everybody fully understands it. 
We heard that in America they tested it on 
monkeys and rabbits but here they test it on 
‘us – it is strange nay [20 year old vaccine 
trial participant] 
Some participants were concerned and worried that vaccines contain an HIV virus that 
infects people with HIV. Below are some of the responses in relation to their worries: 
Testing HIV positive because of the vaccine 
is quite daunting! … the vaccine staying in 
the body for an unknown number of years – 
who knows the long-time effects of the 
vaccine on our health [23 year old vaccine 
trial participant]. 
Some participants indicated that they sometimes get neglected or even stigmatized at 
local clinics because they participate in vaccine clinical trials. Below is an explanation: 
I reported to the research centre that I am sick and I was 
given a referral letter to get treatment from a local … At the 
clinic some nurses do not understand how vaccine work and 
















Community feelings about the vaccine centre and its services were also expressed by a 
key informant from the local clinic: 
… people in our community think that the research centre 
buys blood and inject blood with an HIV virus or some 
people think you get vaccinated and then told to have sex 
with an HIV positive person to test if a vaccine works... 
This makes our community angry … they use our people as 
‘guinea pigs’ to test a thing that is not well known to them 
[key informant, local clinic] 
 
The same sentiments were echoed by a vaccine trial participant who feels scared that may 
be it is true the vaccine contains a virus that might wipe out the black community by 
infecting them with HIV virus:  
I fell sick with fever and my husband thought I was 
pregnant again. But I kept it to myself and when I went 
back to the vaccine centre I was told it was just the side 
effect of the vaccine that would soon disappear [20 year old 
vaccine trial participant] 
Some participants appeared to be nervous when talking about clinic procedures as 
expressed here below: 
Injections are very painful; I feel 
uncomfortable sometimes I get sick with 
headache and my friends in class think I am 
HIV positive so I go to the clinic for ARVs … 














Participants continued to express their fears for clinical procedures are expressed below: 
When the doctor asked me to enter the 
examination room I imagined going through 
this huge machine and seeing other scary 
operating instruments such as cutting blades 
...” [22 year old vaccine trial participant] 
This particular participant was scared of injections during vaccination and blood draws, 
as illustrated below: 
Painful injections and scary blood draws. 
They draw a lot of blood and I am worried 
this may ruin my health... [19 year old 
vaccine trial participant] 
The discomfort about clinic procedures and vaccine side effects was a common concern 
among the vaccine trial participants. But according to the response from one key 
informant from a research centre, these side effects occur for a short while and 
prospective study participants are made aware beforehand and it is documented in the 
consent document that some participants may experience some side effects such as pain 
at the vaccination site, feeling dizzy after blood draw, and so on. 
Psychosocial risks ensuing as a result of stress related to participation in HIV vaccine 
trials include complicated, lengthy trial involving intensely intimate matters, and repeated 
HIV testing. Additionally, anxiety related to exposure to culturally different scientific and 
medical concepts; stress that may result between partners in a relationship as a result of 
the participation of one partner in a trial; stigma and discrimination that may result if 
volunteers’ participation becomes publicly known, and they are perceived to be HIV-












positive HIV test after receiving a candidate vaccine (Newman, Duan, Kathleen, et al., 
2006). 
4.6.3 Inadequate of Knowledge about HIV Vaccines 
Very few participants had knowledge about HIV vaccines trials but had some knowledge 
about previous vaccines such as small pox and influenza. Some participants tried to 
explain how far they understand HIV vaccines:  
I think vaccines are drugs or medicines that are given to 
prevent a certain disease from infecting a person… [19 year 
old vaccine trial participant] 
 
Meanwhile other participants seemed uncertain about HIV vaccines as explained below: 
I do not know what I can call it; I think it is scientific 
medicine tested to see if it prevents HIV infection [23 year 
old vaccine trial participant] 
Some participants wondered why it was important for HIV negative people to be injected 
with an HIV vaccine yet there are other preventive measures such as condoms that can 
prevent people from getting HIV virus. Below are some of the concerns raised: 
Condoms are very perfect why must we be 
injected with something that contains HIV 
virus, commented [Key informant from the 
community] 
Inadequate of knowledge about HIV vaccine trials may be due in part due to the fact that 
some key clinical trial concepts do not directly translate into the local language. This 
cannot easily be understood by most participants whose level of education is lower than 












Words such as “placebo” and “vaccine” seemed to confuse most participants who were 
enrolled in HIV clinical studies, as expressed below: 
To be honest this vaccine ‘thing’ is quite new and not 
everybody I know of fully understands it. We heard that in 
America they tested it on monkeys and rabbits but here they 
test it on ‘us – it is strange nay and for sure some of this 
stuff is hard … Some words [such as placebo] which I 
cannot even explain [20 year old vaccine trial participant] 
The study noted that although it is not certain to assess from the research outcomes based 
on these commentaries about the young women’s involvement in HIV vaccine prevention 
clinical trials, there is evidence that it has contributed to their transformations in sexual 
behaviour. On the other hand such commentaries reflect the rise of a new and powerful 
discussion that stresses women's need to take control over the circumstances that tend to 
place them at risk of HIV acquisition.  
Community concerns are around the issues such as the vaccine containing some particles 
of the HIV virus, as explained below: 
Since we all know that HIV and AIDS are incurable, why then does the 
vaccine containing a virus gets injected into healthy human beings? (Kei 
informant from the community]  
Other participants added: 
Young people want to try things I believe they heard about 
vaccines that prevent HIV infection and they rushed to join 














Some participants reckon that HIV vaccines contain a virus that causes AIDS, as 
illustrated below:  
... I also hear that the vaccine contains HIV, 
is it true? [20 year old vaccine trial 
participant] 
Most participants were concerned that the vaccine is too risky to be injected into the 
blood system: 
In polio it [vaccines] worked – but this is 
risky. Once you get HIV you cannot reverse 
it and this thing is done in such a hurry 
especially here in Africa people do not kno  
much about it [vaccines] [key informant, 
community member] 
Most participants expressed fear regarding security issues as they get targeted by 
community drug dealers who use ARVs to manufacture illicit drugs: 
I have a lot of worries because the 
neighbour’s son now knows that I am a 
participant at the research centre; recently … 
recently a girl was robbed immediately after 
leaving the research centre!! [19 year old 
vaccine trial participant] 
Some participants have a feeling that compensation is not sufficient compared to the risks 
they incur while participating in the studies: 
Compensation to trials participants is not worth it; they 
must be given a lot of money though money is never 
enough to buy life; the volunteers are like soldiers who 
have sacrificed their life – a vaccine is like a bomb on 
their bodies – I will never participate – I am scared [Key 












Some participants expressed fears based on the past experience from previous studies that 
turned out not to be effective and are hence scared to participate in HIV prevention 
vaccine clinical trials. Below are some of the responses: 
I have also heard people say that the vaccine has made 
people get HIV – I know of a girl who tested positive 
after taking that thing [vaccine]; I have also heard 
people say that women who receive that vaccine may 
never have children; I also heard of a vaccine that 
infected people with a virus [Phambili]. Why don’t 
people learn from this experience, especially women? 
[Key informant, community member] 
Participants’ fears especially those related to a vaccine that was believed to have 
increased the number of infections among the participants concur with findings in the 
South African AIDS Vaccine Initiative news release where immunizations in the HIV 
vaccine clinical trial known as the STEP (in South Africa, commonly known as Phambili) 
study was discontinued after Data and Safety Monitoring Board (DSMB) findings that 
the vaccine did not prevent HIV infection nor reduce the amount of virus in those who 
became infected with HIV (Kristen, 2005). 
Due to the uncomplimentary outcome of the Phambili and STEP trials it is likely that 
young people and the general population in South Africa may hesitate to participate in 
HIV prevention vaccine clinical trials. The way in which a vaccine trial is presented can 
vary considerably with differing emphases on risks, benefits, and the burden of trial 
participation. In addition, South Africa is an extremely diverse country and different 













4.7 Attitudes Towards Participating in HIV Prevention Vaccine Trials 
4.7.1 Mistrust of Researchers 
Mistrust of researchers was consistently mentioned by the participants. While most 
participants were clear about the causes of HIV and how it is passed on to people, all the 
participants seemed not to understand the reason why clinical trial sites are based in poor 
neighborhoods such as Nyanga.  
I do not at all trust white people when it comes to their 
relationship with us. Why don’t they test the vaccine on 
themselves first; I heard they want to wipe the black 
community by experimenting on us [20 year old vaccine 
trial participant] 
Some people think that because they are blacks, the whites still continue to abuse them as 
was during the apartheid era: 
… in my community there is a thinking that the white 
people are using us [blacks] to do experiments … [CAB 
member] 
Cultural beliefs affect the way some people perceive scientific research and this 
sometimes affect the lev l of participation in clinical research. Fears surrounding cultural 
beliefs were cited as below: 
I have heard people say that white people practice cultism 
and they use our [black people] … why do they use the poor 















This particular participant does not understand the concept of clinical trials as expressed 
below: 
How do you know that the vaccine is working if they use 
condoms as well? For a study to be accurate they must test 
to ascertain if it works … ayi ayi I will never put myself at 
risk being vaccinated with drugs [Key informant, local 
clinic] 
 
A participant who also said is living with HIV positive thought otherwise about HIV 
vaccine clinical trials. She wondered why researchers should not focus on finding the 
cure and help the already sick from dying.  
Below is the illustration: 
Some people think it is a good idea to help find a vaccine 
that may prevent HIV infection; meanwhile others feel it is 
a waste of money instead that money must be used to treat 
people who already have the virus than waste the money on 
people who are not sick … [Community outreach worker] 
Some participants had a feeling researchers are taking advantage of the fact that they are 
disadvantaged so they use them for their scientific experiments, as pointed below: 
The government should get involved in these clinical trials 
because it is the government’s constitutional duty to look 
after its citizens. But research has been left in the private 
sector and international NGOs who aim at profiteering 
from the poor people. The poor people are being exploited 
















4.7.2 Safety of the vaccine 
Some participants think the vaccine may contain an HIV virus and hence risky for 
human, as explained below: 
…where was the vaccine tested? Tested in monkeys…? It 
would be fair if they tested in other people in the US before 
they test in our ignorant people here in the township. I know 
in the polio epidemic it worked, but this HIV one is risky … 
once you get HIV you cannot reverse … [Key informant, 
local clinic]. 
Participants displayed the lack of or limited knowledge about HIV vaccines by asking 
questions such as: 
“Is it true that Americans manufactured the HIV disease and 
have now put it in a vaccine to kill blacks [18 year old 
vaccine trial participant].  
A point of concern to the researcher was that despite the research centre being in their 
community most participants seemed not to understand what was being done in that 
clinic. Most of the community members live by guesses as expressed here under: 
This vaccine centre has been in our community for a 
number of years but we as the community do not 
understand why they are here. That is why we do not trust 
anything to do with the vaccine centre [key informant, 
community member] 
Some participants feel there is wide information gap between the community and the 
researchers because even though a research centre exists in their community, most people 













This participant expressed herself as follows: 
… Researchers must tell us about HIV prevention to 
make us understand how it works and how it can help us 
in our community... I think they are up to “something” 
[key informant, community member] 
The issue of mistrust and using blacks coincides with sentiments from studies by Jenkins 
(1985) who emphasizes that researchers tend to recruit participants from less privileged 
populations. In developing countries some communities, arguably fall within this 
category. It is important to ascertain whether individuals or communities trust the source 
of information to represent the risk accurately, and this trust is influenced by whether an 
individual or group has had a history of positive or negative experiences with the health 
system, with law enforcement, with research institutions, or with government. In 
resource-poor settings where HIV prevention trials are being conducted, it is critically 
important to recognize the historical backdrop of colonialism and racism, and on-going 
challenges of poverty and exploitation. In this light, building and maintaining trust among 
researchers, communities, and participants can be a critical element of informed consent 
(Shapiro & Benatar, 2005). 
Despite these concerns, participants were in support of finding HIV prevention measures 
but suggested effective communication strategies between the community and 














4.7.3 Inadequate Knowledge About Vaccines 
Some participants were concerned that information about vaccines has not reached 
everybody and this leaves gaps in information dissemination. Even those who seem to 
have received some information about HIV prevention vaccine trials still feel they do not 
understand some concepts. 
Some of this stuff is hard; sometimes the medical 
researchers give us things to read I just listen because I 
want to be part of the study. Some words [placebo] 
which I cannot even explain [19 vaccine trial 
participant]. 
Another participant adds: 
I would support the idea if I am told what vaccines are and 
the importance of HIV vaccines to our people. I do not 
accept things just because they are here in the community 
… [key informant, community member] 
Some participants suggested that researchers develop a video to present basic trial 
information and explain difficult concepts because they felt that a video would be more 
engaging and informative than print material which may not be easily understood by 
most people in the community, most of whom with low literacy levels.  
4.8 Normative Beliefs Influencing Participation Vaccine Clinical Trials 
In this research, I have utilized renowned behavioural theories, the Theory of Reasoned 
Action (TRA) and Theory of Planned Behaviour to explain the connection between 
people making a decision to participate in clinical trials and how other people influence 













4.8.1 Behavioural Beliefs 
Perceived “social pressure” (Ajzen & Fishbein, 1980, p. 246) to perform behaviour or 
forego it, is reflected in the “subjective norm” construct. In this research, participants 
were asked if they thought people, including family and boyfriends, neighbours or 
community friends, might influence their participation in clinical trials. Responses 
include: 
The community sometimes negatively judges those who 
participate in HIV vaccine clinical trials [23 year old, 
vaccine trial participant] 
Some participants are influenced by people closer to them to make decisions to either 
participate or decline to participate in HIV prevention vaccine clinical trials as illustrated 
below: 
My boyfriend and my mother family were bitter because I 
was risking my life to get injected with the unknown drug 
[19 year old vaccine trial participant]. 
While some participant reported being discouraged by their partners some reported that 
their partners were supportive to their participation in HIV vaccine clinical trials: 
Some young women say partners are supportive while some 
women report to have been dumped by their partners after 
discovering that they are participants in clinical trials; [key 
informant, vaccine research centre] 
The researcher found out that there are some influential people in the community that 
participants seek advice from before they make decisions, as illustrated here: 
The pastor is preaching about people who do not trust in 
God and they keep trying other things [vaccines] [20 year 












And because they trust their people they fear losing them due to their participation in 
HIV prevention vaccine trials. Some of these may be bread winners: 
My boyfriend does not approve of my participation and I 
am afraid if he finds out that I am still visiting the research 
centre he might leave me… [20 year old vaccine trial 
participant] 
The issue of boyfriends influence in decision making …… 
It is my boyfriend, how do I tell him that I am a participant 
in a vaccine trial and yet he believes it is risky [injecting 
people with HIV vaccines … [22 year old vaccine trial 
participant] 
 
4.8.2 Beliefs about HIV Vaccines 
Participants were also asked what their own intentions were on deciding to volunteer in 
the HIV prevention vaccine trials. Several questions measured volunteers’ salient beliefs 
about their role in HIV vaccine research. Most of their responses were basically due to 
their self-motivation and interest. The illustrations below show some of these responses: 
 I want my community to benefit from modern science so 
my participation is a contribution to achieve this [20 year 
old vaccine trial participant] 
Another participa t adds: 
I decided on my own but later I also asked a friend just to 
make sure I was making the right decision… [18 year old 
















4.8.3 Normative Beliefs  
Other participants highly applauded their parents, spouses and community leaders to have 
supported them to participate in HIV prevention vaccine clinical trials as explained 
below: 
My ward councillor approved of my participation and he 
asked if I could talk to other youths in our community [20 
year old vaccine trial participant] 
Some participant felt motivated by their parents and siblings to participate, as illustrated 
below: 
My mother has been supportive all the way, the same to my 
brother so I feel encouraged [19 year old vaccine trial 
participant] 
While some participants were being discouraged to participate: 
Yes my mum. She was very bitter that I could make such a 
crazy decision. She even shared this with my boyfriend and 
they turned against me [22 year old vaccine trial 
participant] 
Beliefs that vaccines make participants barren is yet another issues mentioned: 
My boyfriend wants me to get another child but I was told 
that once enrolled I must not conceive until such a time that 
I will be told to do so. This worries me so much and makes 
me think I am doing a wrong thing [23 year old vaccine 
trial participant] 
Some participants think that if they had enough resources they would not participate in 













Below is an illustration: 
… I told you that because of poverty our people especially 
the young ones go into things without even knowing what 
they are going into. How many of the young people in 
Nyanga here are employed…? [Key participant, local 
clinic] 
4.8.4 Motivation to Comply  
In some cases individuals might declare a willingness to participate or reluctance to get 
involved due to general compliance with referent opinion. The theorized influence of 
family, friends, and others on behavioral performance sometimes exerts social pressure to 
act or engage in avoidance. Some of the items measuring this domain include responses 
such as: 
 I always pay attention to what people expect of me, even if 
I don’t know them, “I just want to obey my family and act 
as it pleases them, they always trust in me [19 year old 
vaccine trial participant];  
According to the Theory of Reasoned Action, formation of individual attitude is affected 
by behavioural beliefs and evaluation of behavioural outcome (Montano & Kasprzyk 
2002). The salience of these beliefs combines with the social factors and normative 
beliefs and motivation to comply and is weighted in relation to each other. The addition 
of the social component is useful for prediction of health behaviour outcomes, 
particularly as the approval or disapproval of referent others and importance accorded to 













4.9 Risks, Challenges and Barriers for Participation in Vaccine Clinical Trials  
Numerous factors such as ethnicity, socio-economic status, and sense of agency, usually 
influence how individuals assess risk and the actions they take as a result of their 
participation in HIV vaccine clinical trials. An essential effect to risk assessment is 
whether individuals or communities trust the source of information to represent the risk 
accurately. This trust is influenced by whether an individual or group has had a history of 
positive or negative experiences with the health system, with law enforcement, with 
research institutions, or with government. 
4.9.1 Potential Physiological Risks 
Some participants are not only worried about vaccine, but also using contraception for 
more than 2 years as expressed below: 
Taking a vaccine for two years is risky because I was not 
told how it works while inside the body. Using 
contraceptives puts me at risk of not getting pregnant and 
this may affect my relationship with my boyfriend… [18 
year old vaccine trial participant] 
 
Some young people participants were concerned about these risks as explained here 
under: 
When I received a vaccine injection for the first time, I 
suffered from body pains, I lost appetite and my boyfriend 













A feeling of uncertainty about not knowing how long the vaccine can stay 
in the blood system makes some participants worry, as explained below: 
My biggest fear is living with a vaccine in my body system 
because when I asked the doctors at the vaccine centre they 
told me they are not sure when my blood will be free from 
the vaccine. I am afraid it might affect my fertility [22 year 
old, vaccine trial participant] 
 
The community has their own interpretation of people who participate in clinical trials as 
explained below: 
The thinking of the community that if you visit a research 
centre you are HIV positive and a ‘danger’ to community 
… [23 year old vaccine trial participant] 
Even in the local clinics there is limited understanding of vaccine clinical trials as 
illustrated below: 
Some of them come to this clinic with complications such 
smelly vaginal discharges,  over bleeding, diarrhea etc … 
The biggest risk is that nobody knows whether it is safe for 
participants to accept vaccines in their bodies and nobody 
knows what long term effects could be!! [Key informant, 
local clinic] 
 
Similar fears were expressed by another participant as shown below: 
Rumour is going around about the negative intentions of 
researchers [white people] to use black people to test their 
drugs and later sell them at very high prices to get profit… 













Some participants felt that with the use of vaccine trials the youth behavior has worsened 
because they no longer care to practice safe sex: 
Some people have become more irresponsible after their 
partners receiving the vaccine; some men believe that the 
vaccine works so why should they use condoms to ‘kill’ 
their sexual pleasure? [Key informant, community member]. 
Some community members’ understanding of how the vaccine works is by trying 
unprotected sex: 
They go and try if it works and they stop using condoms; 
my neighbour friends are now experimenting with HIV 
positive girls to see if the vaccine they was injected into 
them works [Key informant, community member] 
These findings are consistent with UNAIDS (1998 & 2000) reports cited in Slack C et 
al., (2000) that highlight potential psychosocial and physiological risks emanating as a 
result of participating in HIV clinical trials. Physiological risks include rapidly 
progressing or established infection if a vaccine is subsequently exposed to HIV (Slack et 
al., 2000). Psychosocial risks include inconvenience and participation fatigue associated 
with lengthy research; anxiety induced by repeated HIV testing;  stress caused by 
exposure to culturally unusual medical and research concepts; vaccine-induced sero-
positivity  in conventional screening methods and associated negative consequences, such 
as the potential for discrimination in employment, and a false sense of security leading to 
increase in risky behavior; and stress between partners as a result of the participation of 













4.9.3 Barriers and Challenges for Participation in HIV Vaccine Clinical Trials 
Noticeably, several stigma-related barriers to participation emerged among all 
participants and these include the notion that volunteers are often labeled by family and 
community members to be HIV positive because of their participation in HIV vaccine 
clinical trials. There is also public perception about pharmaceutical companies whose 
interest is about profiteering from HIV vaccines at the expense of the vulnerable 
populations. A major concern that featured in almost all the responses was vaccine-
induced sero-positivity as explained in the respondents’ explanations below: 
I am also worried that may be it is true that the vaccine 
contains a virus that causes HIV … Why is it that some 
people turn positive – I am worried if I am one of them 
my husband will not believe that I did not cheat on him 
[20 year old vaccine trial participant] 
Similarly, another participant had this to say: 
 What I have heard from the community is that the vaccine 
contains an HIV virus how they can do that to our 
community [24 year old vaccine clinical trial] 
Some participants complained about the risk of getting anemic because of too much 
blood draws as illustrated here: 
Most of them complain about time and the amount of blood. 
At every visit approximately 10 tubes of blood is drawn; 















Another participant said that acceptability of vaccine trials has been negatively publicized 
by the media. Below is his explanation: 
During the microbicide studies African women were 
portrayed as being used ‘guinea pigs’ by the media” 
[Key informant, local NGO].   
Some participants suggested that the media send out good messages to the community if 
it is going to limit the success in solving the issue of vaccine trials. It was also mentioned 
that there exists some form of disengagement between researchers and the community 
they serve and that in most instances researchers feel they have all the answers and 
disregard community views and concerns. Further still, it was mentioned that certain 
categories of people such as men who have sex with men (MSMs) get discriminated and 
worse still, raping lesbians help escalate the spread of HIV. Below are related comments: 
We all have fundamental human rights have a right to 
choose … evangelicals think gay is ‘evil’ [Key informant, 
local NGO] 
4.9.3 Benefits Related to Participating in HIV Prevention Vaccine Clinical Trials 
The most common benefits mentioned by the participants include reimbursement and 
clinical care, as illustrated below:  
Before I joined the vaccine trials I did not know my HIV 
status and blood pressure. After joining the trials I was 
tested for “everything” in my body. … I get money to me it 














To some participants, the financial re-imbursement received supplements their family 
meager incomes, as explained below: 
My husband earns little money as a security guard so I also 
get my own money to buy my own ladies stuff which he 
cannot buy for me [20 year old vaccine trial participant]. 
Most participants were happy to mention that they have access free medical services as 
explained below: 
I am given from free medical examinations and advice in 
case of any sickness… [23 year old vaccine trial 
participant] 
Some participants thought that participants benefit in terms of accessing knowledge about 
HIV prevention, as illustrated below: 
Benefits may be there but indirect. Participants are 
equipped with general knowledge about HIV and how to 
take precautions about protecting themselves from getting 
infected; the services such as risk reduction helps shape the 
young women’s behaviour especially when it comes to 
sexual issues… [Key informant, research centre] 
However, some respondents have a feeling that the poor communities are being taken 
advantage of and they do not see any benefit for participants, as explained in the 
quotation below: 
If there are any benefits I do not know. What I know is that 
the researchers benefit from the participants. If the vaccines 
are found to be effective, of course the researchers will 














To some participants it is just the question of being poor so they participate to earn a 
living as explained below: 
… if I am poor and I am earning some cash study every visit 
I am participating for sake of survival; they are actually not 
empowered with all the information. Communities do not 
understand the science... [Key informant from local NGO] 
Worth noting was the way young people appreciated the power and ability to control their 
lives. Studies indicate that originally HIV was perceived as an uncontrollable and 
inevitable epidemic, without hope (LeClerc-Madlala, 1997). However, based on the study 
findings conducted among the in among some youth in South Africa showed change in 
perception about getting infected with HIV. A study conducted among university students 
revealed that about 37 per cent of Durban university students saw reason to change their 
sexual practices in order to avoid AIDS, and only 17 per cent considered themselves at 
risk for HIV infection (Naidoo et al., 1991 cited in Varga, 1998). 
Nearly two-thirds of youth people stated they wanted to make some behavioral change, 
such as abstinence, monogamy or condom use, to decrease the risk of HIV infection. 
Relatedly, some participants confessed to be in charge issues regarding making sexual. 
This was attributed the fact that they are empowered with knowledge from researchers. A 
young woman testifies: 
Every visit at the clinic the counsellor talks to me about the 
dangers of having sex without a condom, sex under the 














4.9.4 Knowledge of Rights to Participation in HIV Prevention Vaccine Clinical Trials 
The following responses exhibit some of the legal rights that the participants highlighted 
in the interviews with the researcher: 
I have a right to participate or decline if I want to … trials 
[23 year old clinical trial participant] 
I can say no to certain things such as injections and blood 
withdrawals; I have a right to privacy … [18 year old 
clinical trial participant] 
Community Advisory Board (CAB) members are the link between researchers and the 
community and are expected to inform the potential about research procedures. These are 
some of the expectations: 
… I presume the CAB and community out-reach team 
inform them of their rights but as nurse I am quite aware 
that volunteers can terminate their participation anytime 
they so wish … [Key informant, research centre] 
Some community members appear t  be informed about the participants’ rights, as 
explained below: 
What I know is that they have a right make choice whether 
to participate or not … [Key informant, community 
member] 
But knowing their rights is directly linked the way messaging is communicated to the 
communities, as explained below: 
 It depends on what kind of messaging goes out there to the 
communities … [key informant, community NGO] 
Most participants admitted to have been told about their rights as participants. However, 












compromised even on their own rights because they cannot make independent decisions. 
The researcher also found that participants were not familiar with the concept of 
vaccination and this is a clear manifestation that due to low literacy levels of the 
participants they do not understand the language used in the consent document in which 
rights and obligations of the trial participants are outlined. Responses in this regard are 
illustrated below: 
I was told that I can decide to leave whenever I want to. But 
I do not know whether they meant that it will not affect my 
life because I have already taken two injections; how about 
if I fall sick afterwards because of the vaccine will they help 
me get medical treatment [20 year old vaccine participant] 
Another key informant thinks it is the right of the community in which HIV vaccine trials 
are conducted to take full participation in the trial process and also to have the 
government respond to structural barriers that contribute to the HIV prevalence in 
communities: 
There is need for active participation at grass level, 
localized campaigns, in communities major concerns 
include food, water; only one in 8 in a family is employed, 
TB in the house without windows… mass voices, 
accountability civil society to hold government to 
accountable and mobilization of all sectors is required  
















4.10 Policies and Legislative Framework on HIV Vaccine Clinical Trials 
Most participants indicated that they have no or inadequate knowledge about policies that 
are concerned with the development and administering of HIV vaccines in the country. 
Below are some of the responses: 
I know nothing about policies [20 year old vaccine trial 
participant] 
Similarly this participant explained: 
I even do not know what policies is I do not know [19 year 
old clinical trial participant] 
This particular had at least head about ARVs as explained below: 
I heard about HIV law of giving people ARVs but this one 
of vaccines I do not know [22 year old clinical trial 
participant] 
Participants from well-established institutions lso seemed to have limited knowledge 
about existing policies on HIV vaccine trials as shown below: 
I only know that the government has put in place the 
National Strategic Plan (NSP) (2012-2016 that guides the 
national response to HIV, STIs and TB; the Health 
Research Policy in South Africa promotes practice and 
conduct of research [key informant, research centre] 
Community Advisory members (CABs) who happen to be the link between the 
community and the researchers were not quite sure whether participants have knowledge 
about policies governing clinical trials as illustrated below: 
… No. But I doubt whether the participants know about this 
policy or law [CAB member] 
Policies create frameworks for identifying objectives and setting priorities and define the 












organizations such as UNAIDS and the Global Fund, national HIV programs and 
committees throughout the world have developed HIV and AIDS frameworks that 
establish national priorities in responding to the epidemic. These frameworks include 
goals for national prevention programs and provide the basis for coordinating the work of 
all partners. 
The government has put in place general policy guidelines such as the National Strategic 
Plan (NSP) (2012-2016), whose strategic objectives include addressing social and 
structural barriers that increase vulnerability to HIV, STI and TB infection. The Health 
Research Policy in South Africa has been developed to prom te practice and conduct of 
research that contributes towards the improvement of the human health and welfare of the 
South African population. At a macro level, the 2009–2014 Medium Term Strategic 
Framework (MTSF) sets out the strategic mandate of government.  In addition, the 
National Planning Commission is currently developing a broad government framework 
for addressing the major developmental challenges in South Africa, while at the 
international level the MDGs have specific targets that all countries are striving to 
achieve by 2015.  
It was noted, however, that although the various policies exist on national and global 
levels the participants do not seem to understand and even have knowledge of such laws. 
Studies have also shown that although South Africa has a functioning ethical-legal 
system with the necessary institutions and some of the guidelines, but does not have 












research, including HIV vaccine trials (Strode, et al., 2005). On that basis, the researcher 
adds that policy documents should be communicated to various constituencies in the 
simplest language possible for them to understand. It is worth noting weak policies may 
lead to the increase of vulnerability to exploitation of HIV clinical trials participants and 
communities in South Africa and elsewhere in the world where HIV prevention vaccine 

























CONCLUSION AND RECOMMENDATIONS 
Chapter five presents the conclusions and recommendations from the research findings. 
The conclusions drawn from the research findings will be presented in relation to the 
research objectives. 
5.1 Behavioural Beliefs, Motivations and Benefits 
To understand subjective norms that influence young women’s participation in HIV 
vaccine clinical trials, the study utilized renowned behavioural Theory of Reasoned 
Action (TRA) and Theory of Planned Behaviour (TPB) to explain the connection 
between people making a decision to participate in clinical trials and how other people 
influence their decision to participate. 
The major conclusions drawn from the findings regarding reasons that motivate young 
women to participate in HIV prevention clinical trials include getting protection from 
getting infected with HIV. Most participants’ responses indicated that their motivation 
was derived from the urge to get protected from HIV infection. Most of the young people 
were of the view that getting an HIV vaccination gives them protection from HIV. This is 
contrary to the information from some key informants who were of the view that that 
young people should not only participate in HIV vaccine clinical trials to get protected 
from contracting HIV but they must also practice safe and protected sex because there is 













5.2 Monetary Gains from Participation in HIV Vaccine Clinical Trials 
Another aspect that participants consider in order to join clinical trials is because of the 
monetary re-imbursement. Majority of the respondents were in agreement that most HIV 
prevention vaccine clinical trials participants get attracted to join because of they get 
some financial re-imbursement for their time and transport. Key informants were equally 
in agreement saying that due to the socio-economic conditions in which the participants 
find themselves they rely on the money that they receive to meet some of their basic 
requirements. 
5.3 Access to Medical Care  
Most participants in this study admitted that it is easy to get medical care from the 
research centre than in the public local clinics. Most key informants were in agreement 
with the young people saying getting medical care from the public clinics and hospitals is 
quite frustrating so people turn to private health providers if they have money. But most 
of the participants reported to be unemployed so they get free health care services from 
the vaccine research centre. Similarly some key informant participants agreed that their 
focus in the vaccine centre is mainly on health issues such treatment of STIs, giving 
family planning contraceptives, etc. The researcher found out that women who attend the 
vaccine clinical trials have been somehow empowered to control their health issues by 














5.4 Altruism to the Community 
The responses by the young people also concur with some of those from the key 
informants who admit that some women have taken a firm stand against HIV and they 
have demonstrated this partially by volunteering in HIV prevention vaccine clinical trials 
to help find an effective vaccine. 
5.5 Getting Access to Information about HIV  
Almost all respondents admitted that the information they get at the vaccine centre has 
helped them change their behaviour regarding getting involved in risky behaviour that 
may expose them to getting HIV. Some key informants also agree to that effect although 
one key informant had different views, “when your girlfriend gets vaccinated you are 
sure of protection from getting HIV from her and free to have sex without a condom”. 
As regards perceptions in participating in HIV vaccine clinical trials some participants 
were in agreement with the fact that vaccines may be helpful to the community. Some of 
them even cited the past year vaccines that now prevent children and adults from dying 
(vaccines for polio and influenza). In this case participants are hopeful that one day 
vaccines that prevent the dreadful HIV will be found to the joy of the whole world. 
However some of the respondents think HIV vaccines may be harmful to participants 
hence they decline to participate.  
5.6 Barriers and Fears 
Some of the participants pointed out that HIV vaccine clinical trial contain a virus that 












conducted. However, some key informants such as research nurse and CAB members 
reiterated that this is a misconception spread in the community about vaccines and HIV 
vaccine clinical trials.  
5.7 Lack of Adequate Knowledge about Vaccines 
Based on the responses from participants, it is pertinent to note that the majority of 
participants are not knowledgeable enough about the clinical trials neither are they aware 
of their rights and benefits, save for some few who said they know their rights. On the 
contrary, some key informants especially those working in the HIV clinical research 
affirm that participants know their rights. To the researcher this gives an insight that 
participants and the wider community have not received enough information about HIV 
vaccines.  
Due to inadequate knowledge in the community regarding HIV vaccine and clinical trials 
people have their own understanding of what vaccine clinical trials are. Some insinuate 
that this is a plan by the United States to wipe out the entire African continent where the 
majority of black people live. Another misconception is that the HIV vaccine contains a 
virus that causes HIV and the white people are testing in black people for experimental 
purposes. These controversies are being over-turned by community educators and CAB 
through creating awareness among the communities. 
In terms of young women’s attitudes towards participating in HIV vaccine clinical trials, 
the study found that few participants seemed to understand research concepts used in 












education has been given to research participants and hence they expect them to 
understand these concepts since they have been translated in the local language used by 
the research community. But based on the demographic information of the participants it 
is very clear that most of them are not literate enough to read and understand clinical 
research terminologies. 
5.8 Misconceptions about HIV Vaccines  
The study found that there are increased incidences of high risky behaviour. Some 
participants testified that men whose spouses or partners are on HIV vaccine clinical 
trials tend to believe that their partners are protected so they get as many partners as they 
can and this renders them vulnerable to getting infected. Some participants also once they 
have gotten the trial vaccine go and “try to see if it works” because to them the vaccine is 
meant to prevention infection. This kind of practice increases incidences of HIV 
infections in the community. 
5.9 Trust Issues due to Historical Trauma 
Participants consistently mentioned that they do not trust researchers who have chosen to 
conduct research in the poor areas such as Nyanga Township. Accordingly, as explained 
by some participants, mistrust of clinicians has to do with the past history in South Africa 
where the apartheid policies tended to undermine the black people. For that matter people 
in black townships in South Africa still have that belief that whites take advantage of 












dissemination of relevant information the community about vaccine clinical trials. The 
community needs to know the importance of HIV preventative vaccines. 
Most participants indicated that for the most part they made their own decisions to 
participate in the HIV prevention vaccine clinical trials. This was attributed self-
motivation and interest in the research aimed at discovering an effective HIV prevention 
vaccine. Key informants had similar views about participants being driven by enthusiasm 
and commitment to participate in the fight against HIV. However, in most African 
communities, women do not make decisions without consulting. This may also apply to 
men as well. So according to the participants they had to consult referent others in order 
to make decisions. Such consultative processes gives an insight of how some African 
culture rely on collective decision making mechanisms. 
Lastly, individuals might declare a willingness to participate or reluctance to get involved 
due to general compliance with referent opinion. Most African people live and survive in 
a web of socialized family and friends networks that they do not wish to break. In this 
case they consult and get approval before decisions are made. 
5.10 Risks to Participation in HIV Vaccine Clinical Trials 
The study identified numerous factors in regards to risks in participating in HIV 
prevention vaccine clinical trials. These include ethnicity, socio-economic status, and 
sense of agency, and these influence how individuals assess risk and the actions they take 
as a result. Among the risks mentioned by the study participants are mistrust of the source 












with government. Other classifications of risks include potential physiological risks and 
psycho-social risks which occur as a result of stress related to participation in 
complicated and lengthy clinical trial procedures. 
5.11 Challenges Encountered by Vaccine Trial Participants 
Participants expressed a variety of challenges as a result of their participation in HIV 
vaccine clinical trials. Noticeably, several stigma-related barriers which include the 
notion those volunteers are often labeled by family and community members to be HIV 
positive because of their participation in HIV prevention vaccine clinical trials. A major 
concern that featured in almost all the responses was vaccine-induced sero-positivity. As 
far as benefits related to their participation, the most commonly identified ones include 
financial incentives and access to medical care and treatment. On that basis, the medical 
ethical guidelines emphasize that efforts must be made to maximize the potential benefits 
of HIV vaccine research in order to avoid exploitation of vaccine clinical trial 
participants.  
5.12 Rights to Participation in HIV Vaccine Clinical Trials 
Although some participants seemed to understand what their rights are regarding their 
participation in HIV prevention vaccine clinical trials, it was feared that this may just be 
on paper but practically if they refuse to take directives from the researchers they may 














5.13 Policies Guiding HIV Vaccine Clinical Trials 
Regarding policies and legislative frameworks guiding HIV vaccine clinical trials, almost 
all participants including the key informants had little or no knowledge about policies 
that guide the HIV vaccine clinical trials. This is clear evidence that the government has 
not intervened enough in the area of HIV vaccine clinical trials.  
The importance of decolonizing and indigenizing the research process has been stressed 
as a guide to guide the development of mutually beneficial research partnerships with 
indigenous communities (Karina, 2008). Principles for decolonizing and indigenizing 
research include reflection, respect, relevance, resilience, reciprocity, responsibility, re-
traditionalization and revolution. It was also emphasized that for research to be relevant, 
researchers must educate the community in order to minimize misconceptions and 
guesses about clinical research (Karina, 2008).    
The study therefore identified issues of promoting women empowerment processes so as 
to equip potential clinical trials participants with the knowledge and power to make 
informed decisions without having to rely on their male counter-parts. The researcher 
recommends that consideration be made to involve men in education and awareness 
programmes regarding HIV clinical trials to avoid misconceptions and suspicions about 
women participants as being promiscuous or having HIV, which usually culminates into 
domestic violence against women.  
According to the Belmont Report (1972) persons who are economically or socially 












they are to be used adequate justification is required for the involvement of subjects such 
as prisoners, students, subordinates, employees, and service personnel etc. who have 
reduced autonomy as research subjects. The report emphasized that the justification for 
including a vulnerable group in research is when a problem disproportionately affects that 
group (Belmont Report, 1972). It is therefore important that researchers follow 
internationally recognized guidelines by the Nuffield Council on Bioethics (1999) which 
stipulates that research organizations should not exploit the vulnerable populations in 
which clinical trials are conducted.  
The international bioethics guidelines on health research disregard the idea of researchers 
selecting populations which are economically or politically weak, and therefore 
vulnerable to exploitation (Benatar, 2000). The echoes similar sentiments on bioethics 
guidelines and adds that before clinical trials are conducted, the communities in which 
clinical trials are to be conducted require on-going sensitization around the risks, benefits 
and rights expected of them as study participants in vaccine clinical trials. 
The study participants did not give substantial responses around the issues of policies on 
HIV vaccine trials hence the government needs to put more emphasis these aspects.  
As a social responsibility, researchers should also focus on helping the young women 
acquire life skills and income generating projects to alleviate the level of dependence of 













5.14 Summary and Conclusion 
It is quite evident that humankind is relentlessly challenged by the HIV epidemic which 
has mystified humankind in various aspects. Based on this fact the HIV and AIDS 
epidemic needs to be confronted in a more collective and sophisticated manner. Recent 
research has shown that one of the key weapons in eradicating this scourge is to develop 
an effective HIV vaccine. But this has be done by engaging all the key stakeholders such 
as study participants and the community at large having to play as active role in vaccine 
design and development.  
This study found that most study participants do not have sufficient knowledge regarding 
HIV prevention methods such as vaccine clinical trials. Although a few participants were 
able to tell what vaccine trials they have been enrolled in, most participants still do not 
understand the importance of HIV vaccines clinical trials done HIV negative people and 
yet much intervention is required to treat the already HIV positive people from dying. 
This shows that knowledge gaps exist and if not addressed it may in the long run affect 
the noble cause of trying to find the ever lasting solution towards eliminating the deadly 
killer HIV disease. It is fundamental therefore to ensure that relevant education and 
information is disseminated to communities in which these vaccine trials are conducted if 
any fruitful results are to be achieved. The researcher also recommends further research 
and investigation to explore more about the perceptions and experiences of young people 
in other provinces of South Africa in order to get an in-depth understanding of the 
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Appendix 1: Consent Form for Participation in Research 
Title of study: An Exploration of young women’s perceptions and experiences of 
participating in HIV and AIDS prevention vaccine trials in Nyanga Township in the 
Western Cape, South Africa 
Researcher name:  Nandudu Norah 
Department:   Social Development – University of Cape Town 
Course name:   Masters Social Development 
Invitation to Participate & Study Description 
As one of the participants/community leader/service provider/spouse to participant/other, 
you are requested to participate in a research study about an exploration of young 
women’s perceptions and experiences of participating in HIV and AIDS prevention 
vaccine trials in Nyanga Township in the Western Cape, South Africa. 
This study will help us better understand how and why young women make decisions to 
participate in HIV vaccine clinical trials and their experiences about these trials. By 
agreeing to participate in this study, you are agreeing to be interviewed about issues 
surrounding HIV vaccine trials. Each interview will take about an hour to complete and 













Risks and Benefits 
This study does not involve any type of physical risk; you will be asked to answer 
questions about your experiences and perceptions about HIV vaccine clinical trials and 
the information you contribute will help us better understand how young women make 
decisions to participate in clinical trials. The information from this study will only be 
used by researcher and supervisor of the University of Cape Town for academic 
purposes.  
Confidentiality 
The information you provide will be kept strictly confidential. To protect your privacy, 
your responses to the interview questions will only be identified with a pseudo names and 
will be kept by the researcher. All research outcomes will be kept for five years after the 
study has ended and will be accessible only to the researcher and the university 
supervisor. Your name will not be associated with the study materials or with the 
research findings. The information obtained in this study may be published in scientific 
journals and presented at professional meetings, but only group patterns will be described 
and your identity will not be revealed. 
Right to refuse or withdraw 
The decision to participate in this research project is entirely up to you. You may refuse 
to take part in the study without affecting your relationship with anyone. You may also 












Right to ask questions 
You have the right to ask questions about this study and to have those questions answered 
by the researcher before, during or after the research.  
Consent 
Your signature below indicates that you have decided to participate voluntarily this study 
and that you have read and understood the information provided above. You will be 
given a copy of this form to keep. 
You must be 18 years of age or older to take part in this research study. 
I agree/do not agree* to the tape/transcript* being made available to me by the researcher 
(* delete as appropriate) 
Name of Participant (Please print): ……………………………………………………… 
Participant’s signature: ……………………………  Date: ………………………….. 
I certify that I have explained the study to the participant and consider that she/he 
understands what is involved and freely consents to participation. 
Researcher’s name ……………………………………………………………................. 














Appendix 2: Interview Schedule 
I want to thank you for accepting to take time and meet with me today. My name is 
Norah Nandudu and I would like to talk to you about your experiences participating in 
the HIV vaccine clinical trials. Specifically, this study is about an exploration of young 
women's perceptions and experiences about HIV vaccine.  
The interview should take less than an hour. I will be taping the session because I do not 
want to miss any of your comments. Although I will be taking some notes during the 
session, I cannot possibly write fast enough to get it all down. Because we are on tape, 
please be able to speak up so that I do not miss your comments. 
All responses will be kept confidential and I will ensure that any information I include in 
my report does not identify you as the respondent. Remember, you do not have to talk 
about anything you do not want to and you may end the interview at any time. 
Are there any questions about what I have just explained? 
Are you willing to participate in this interview? 
If yes, let us get started and I am going to switch on the tape recorder. 
 Tell me about yourself 
 How did you hear about HIV vaccine clinical trials? 












 Tell me about your own thinking and experiences of HIV vaccine clinical trials? 
(probe) How have your experiences as a study participant influenced or not 
influenced you in the decisions that you made to participate?  
 What other factors influenced you to make a decision to participate or not to 
participate in HIV vaccine clinical trials? (Please give examples)  
 What challenges/barriers related to participating in HIV vaccine clinical trials 
have you so far been faced with?  
 Do you have any knowledge regarding the risks, benefits and rights related to 
your participation in HIV vaccine clinical trials?  
 Of all the things you described to me about your experience in participating in the 
trials, what issues did strike you most? (Probe)  
 Is there anything more you would like to add?  
 What recommendations do you have for future efforts such as these?  
 After analysing the information you and others interviewees gave me and 
submitting a report to the university I will be happy to send you a copy if you are 
interested.   
Thank you for your time. 
 
